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ABSTRACT OF DISSERTATION 
 
 
UNDERSTANDING THE THERMODYNAMICS  
AND ORAL ABSORPTION POTENTIAL OF  
PHARMACEUTICAL AMORPHOUS SOLID DISPERSIONS 
 
Supersaturating drug delivery systems, such as amorphous solid dispersions (ASDs), 
have been used extensively to elevate the apparent solubility and oral bioavailability of 
poorly water-soluble drugs. However, despite the numerous examples of success in 
increasing solubility and oral bioavailability using ASDs, physical stability challenges 
remain as formulators seek to employ high drug loading for cost reduction and improved 
patient compliance. Therefore, stability in both the solid and solution state must be 
considered for ASDs to be successful. In the solid state, the drug must remain amorphous 
in the solid matrix throughout the shelf life of the product. Although excipients, such as 
polymers, have been known to stabilize the amorphous drug in the solid state, stresses 
encountered during manufacturing and fluctuations in storage conditions may have a 
detrimental impact on the physical stability of ASDs. Numerous studies have been 
performed on the impact of each process on ASD stability, yet the relative quantitative 
impact of each process with respect to the overall energetics landscape is not well 
understood.  
 
Further, ASDs must dissolve after administration and maintain the intended 
supersaturation in the gastrointestinal (GI) tract during the GI transit time to achieve 
maximum oral absorption. In solution, the energetics advantage of the amorphous over 
the crystalline material is a “double-edged sword,” in that it produces not only a high 
absorption driving force but also an undesirable high crystallization potential. An 
approach to quantitatively measure the thermodynamic activity of amorphous materials 
is, thus, desirable. However, it is difficult to measure thermodynamic activity 
quantitatively, especially due to the speciation process induced by formulation excipients 
and endogenous materials. Hence, it is often difficult to assess the true enhancement in 
the absorption for a given ASD and to measure its crystallization tendency in solution. 
Overall, this dissertation aims to address the following: 
 
1. The relative thermodynamics magnitude of various processes with respect to the 
crystallization energy associated with amorphous drugs 
2. The development of a practical tool to measure the thermodynamic activity of 
amorphous materials over its crystalline counterpart in solution to assess the 
enhancement in absorption in the presence of excipients 
3. The impact of measured thermodynamic activity on drug crystallization energetics in 
the presence of excipients 
 
 
KEYWORDS: supersaturation, crystallization, amorphous, poorly water-soluble drugs, 
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Chapter 1 - Introduction 
 
1.1 Background 
With the goal of producing more efficacious new chemical entities (NCE), the use 
of high throughput screening in the drug discovery space has resulted in a massive 
increase of hydrophobic compounds. As high as 90% of NCEs have been identified as 
being poorly water-soluble, which is inextricably linked to the resulting poor oral 
bioavailability of these compounds [1]. Supersaturating drug delivery systems (SDDS) 
are formulation approaches that have been developed to overcome these solubility issues 
and enhance oral bioavailability [2]. Amorphous solid dispersions (ASDs) are an example 
of SDDS, and their success in increasing oral bioavailability have been well documented 
in the literature [3]. The success of ASD relies upon its solid-state stability throughout the 
processing and storage period as well as its supersaturation stability in solution after its 
administration into gastrointestinal (GI) environment. Despite extensive research on ASD 
solid-state stability, its assessment is a strong function of the sensitivity of the analytical 
tools employed. However, the selection of analytical tools in the pharmaceutical area 
tends to be limited compared to the availability at large. Similarly, while supersaturation 
stability in solution have been widely studied, successful construction of in vitro-in vivo 
correlations (IVIVC) in this space is still minimal. The lack of IVIVC is perhaps mostly 
attributable to the insufficient understanding of the mechanisms by which ASD enhance 
bioperformance in vivo. As such, this review examines the analytical tools available for 
detection of ASDs solid-state failure modes detection and explores the mechanisms by 
which ASDs enhance bioperformance. The knowledge gained from this review is 
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expected to aid formulators in making a scientific-based decision throughout the 
development of ASDs.  
 
1.2 Potential solid-state failure modes in ASD and their detection methods  
An amorphous solid is defined by the absence of a long-range order of 
intermolecular arrangement, an otherwise characteristic property of its stable crystalline 
counterpart. From the solubility theory, dissolution of a solute into a solvent involves the 
energy penalties from the breaking of solute-solute interactions in the solid-state while 
creating a void in the solvent and the subsequent energy gained from placing the solute 
molecule into the solvent void. Since amorphous materials lack long-range order in the 
solid state, the energy penalty associated with the breaking of solute-solute interaction is 
significantly reduced, thus the amorphous solids are said to have a higher free energy 
state relative to the crystalline solid. As a result, the higher free energy of the amorphous 
solids confers a greater solubility and dissolution rate compared to the crystalline form. 
However, this advantage comes with inherent stability liabilities. In other words, because 
of its high free energy, amorphous solids will tend to “seek out” a more stable 
thermodynamic state [4].  
In order to stabilize the amorphous drug, excipients (often polymers) are added to 
create a solid dispersion of drug and polymer. The goal is to create a uniform miscible 
dispersion where each drug molecule is “dissolved” in the polymer matrix, which is also 
known as solid solution. Physical stability of ASDs is governed by thermodynamics, 
kinetics, and drug-excipient interactions [5]. Further, ASD thermodynamic properties are 
governed by the drug heat of fusion, degree of supercooling, and configurational entropy, 
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whereas the kinetic contributions to ASD physical stability are associated with 
translational, vibrational, and rotational modes of motion. The stabilization conferred by 
the added excipients results in a reduction of the dispersed drug activity due to the diluent 
effect and/or favorable drug-excipient intermolecular interactions, which in turn impacts 
the thermodynamic and kinetic properties of amorphous drug in ASDs. The greatest 
challenge with ASD is perhaps its heterogeneous nature that is heavily dependent on its 
“thermal history” (i.e. what is the state of the glass produced?). For example, it has been 
reported that the method by which ASDs are produced, via a melt or solvent evaporation, 
could significantly impact its physical stability [6]. Consider producing an amorphous 
material via rapid cooling of the melt, different rates of cooling would produce different 
states of glass, i.e. glasses with two different Tg’s as shown in Figure 1.1. The difference 
in the glassy states is critical since the glass with the higher Tg exhibits a higher 
energetics. Similarly, solvent evaporation process would generate different characteristics 
of glass depending on the rate of solvent removal as well as the amount of residual 
solvent. Although analytical tools are available to measure the different Tg’s and 
equations have been developed to understand the properties of the different glassy states 
at the operating temperature, the dependence of the glassy state on the processing must be 
recognized. In addition, glassy materials may relax over time, thus the properties of the 
glass may be different compared to freshly prepared glass.  
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Figure 1.1 Specific volume/enthalpy diagram versus temperature for crystalline and two 
glassy materials of the same hypothetical compound. 
 
Furthermore, ASDs undergo further manufacturing processes and exposure to 
storage conditions before distribution to consumers, as shown in the schematic in Figure 
1.2. Mechanical stresses, such as milling, compaction, or compression during 
manufacturing may create imperfections, such as cracks and defects with enhanced 
surface energy, which may induce phase changes in ASD solid matrix. Similarly, 
moisture exposure during storage may change the strength of interaction or activity of 
drug in polymer. Therefore, it is often difficult to make accurate predictions of ASD 
stability since the starting glassy state might be different for different thermal histories 
experienced. Nevertheless, understanding the potential failure modes associated with 
ASDs such as amorphous-amorphous phase separation and crystallization, which may be 
caused by the aforementioned processes, and the awareness of the analytical tools 
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available for detection of these failure modes are critical to the successful development of 
ASD.  
 
 
 
 
Figure 1.2 Schematic of various processes that ASDs may be exposed to and the critical 
attributes associated with each process that may contribute to the solid-state failure 
modes.  
 
1.2.1 Amorphous-amorphous phase separation (AAPS) risk 
 One avenue by which ASDs are de-mixed is through AAPS, a condition where 
amorphous phases of drug-rich and polymer-rich regions coexist. AAPS is believed to be 
a precursor to crystallization [7]. The impact of storage conditions, such as relative 
humidity (RH) and temperature, on AAPS of ASDs has been evaluated in the literature. 
For example, Marsac et al. observed a reversible temperature-induced de-mixing of 
felodipine and polyvinyl pyrrolidone (PVP), whereas an irreversible de-mixing was 
observed with changing RH [7]. Rumondor et al. investigated several poorly soluble 
drugs with PVP and concluded that miscibility could be maintained with low ASD 
hygroscopicity, less hydrophobic drug as determined by the drug’s log P, and strong 
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drug-polymer interaction as determined by ΔpKa of hydrogen bonding acceptor and 
donor [8]. Interestingly, the authors observed that for some systems that underwent 
moisture-induced AAPS, the drug did not crystallize even at a higher RH. Lakshman et 
al. also observed a similar phenomenon where crystallization did not occur despite 
observation of AAPS under accelerated conditions [9]. Perhaps this phenomenon may be 
explained by the slow re-organization step of drug molecules to form a critical nucleus 
for subsequent crystallization processes [7], thus it is intuitive that drug crystallization 
tendency [10] be evaluated early so as to gauge the rate determining step (bulk diffusion 
vs. re-orientation step) for crystallization. On the other hand, process-induced AAPS 
from manufacturing steps has not been extensively evaluated, albeit it is intuitive that the 
variety of forces associated with typical processing have potential to induce phase 
transformations [11]. Poozesh et al. recently utilized focused ion beam scanning electron 
microscopy (FIB-SEM) to investigate particles produced from the same spray drying 
batch and observed a large size distribution with the larger particles displaying drug-rich 
and polymer-rich regions phase separation [12]. In addition, Ayenew et al. observed 
AAPS of a naproxen-PVP system after compression [13]. While some evidence indicates 
that AAPS may not necessarily lead to deleterious crystallization, more research needs to 
be conducted to assess how AAPS influences critical bioperformance characteristics, 
such as dissolution, supersaturation, and absorption, which will be discussed in the latter 
part of this review.  
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1.2.2 Crystallization risk 
 Crystallization from the amorphous phase is characterized by nucleation and 
growth steps. Traditionally, the kinetics of crystallization is described by classical 
nucleation theory. However, due to its many limitations, such as the lack of homogeneous 
nucleation, changing degree of supercooling, or difficulty to evaluate specific variables 
experimentally, other models that simultaneously account for both nucleation and growth 
are often utilized instead. Bhugra et al. has thoroughly summarized this topic [5] and it 
will not be discussed further here. Although mathematical descriptions of crystallization 
have been developed, the typical processing and storage conditions that ASDs are 
exposed to may induce solid-state changes, which complicate the application of these 
theories. Preparation methods (melt quench, ball mill, spray dry) have been reported to 
produce ASDs with very diverse physical stability, although the same Tg was observed 
across all the methods used [14]. Leane et al. observed a difference of at least a 4-fold 
rate of crystallization at the same storage conditions when comparing a direct 
compression product to a product produced by a compression preceded by a compaction 
step, suggesting that process-induced phase transformation occurred [15]. It is also well 
known that crystallization occurs several orders of magnitude faster on the surface than 
that in the bulk [16], suggesting that particle size reduction in the manufacturing process 
may lead to detrimental crystallization due to the higher surface area to volume ratio. 
Other authors have also reported the impact of moisture during storage, albeit the rate of 
crystallization is also a function of the physicochemical properties of the ASD itself [17, 
18]. Regardless of the process by which crystallization may be induced in an ASD, 
crystallization negates the intended amorphous advantage. Therefore, an approach that 
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allows for analyses of ASD physical stability is necessary to evaluate and avoid the 
downstream risk of crystallization.   
 
1.2.3 Analytical tools for ASD failure modes detection 
As mentioned above, understanding the available analytical tools for ASD 
physical stability assessment is critical in the development of ASDs. While numerous 
methods have been utilized in different studies, there has been no unified knowledge on 
the sensitivity of these methods. Herein, a summary of available analytical methods along 
with each of the time and length sensitivity is presented in Table 1.1. It also needs to be 
pointed out that no single analytical technique can capture all information necessary for 
ASD physical stability consideration. In other words, orthogonal approach should be 
utilized to obtain a comprehensive physical stability information. This section is divided 
into three groups of analytical tools: calorimetry, spectroscopy, and microscopy.  
Calorimetric techniques, such as differential scanning calorimetry (DSC) and 
solution calorimetry (SC), measures the energetics associated with each phase change 
that occurs as a function of temperature, e.g. melting or glass transition. Although 
calorimetry has been utilized extensively in the pharmaceutical arena as it readily 
provides the thermodynamic properties of a single component, it is difficult to evaluate 
multicomponent mixtures since the measured calorimetric signal is the sum total of all 
thermal responses. For instance, DSC has been used extensively to demonstrate ASD 
miscibility by a measure of Tg, whereby a multicomponent system is assumed to be 
miscible if a single Tg is observed or immiscible if two or more distinct Tg’s are present. 
To test this hypothesis/assumption, Qian et al. conducted a study on the miscibility of a 
9 
 
poorly soluble compound, BMS-A, and PVP-VA polymer produced via two different 
screw rotation speed of a hot-melt extrusion process [19]. The authors observed that 
although a single Tg was observed for both ASD batches, the confocal Raman 
microscopy data showed that there is a difference in the homogeneity between the two 
batches in that the higher screw speed conferred a much more homogeneous dispersion 
than the other batch, which eventually affected its long-term physical stability. The 
authors then concluded that the single Tg “rule” may not be sufficient in guaranteeing 
ASD miscibility/homogeneity and suggested that an orthogonal approach be used to 
confirm ASD homogeneity. Another potential challenge with DSC is that although a 
single Tg may be observed, the Tg event could be very broad due to the large distribution 
or heterogeneity in the solid matrix [20]. For instance, Kim et al. observed a very broad 
Tg that spanned approximately 65-80°C associated with synthesized gradient 
copolymers, whereas two distinct Tg’s were observed for block copolymers [21]. 
Gradient copolymers differ from block copolymers in that gradient copolymers vary 
sinusoidally in composition instead of constant composition in each “block.” Although 
this particular study did not specifically aim at understanding ASD physical stability, the 
observed broad Tg implied that there are “pockets” of heterogeneity in the system 
analyzed, resemblance of the AAPS phenomenon that may be observed in ASDs. 
Furthermore, heat-induced phase transitions associated with the heat cycle performed 
using DSC may occur. For example, Marsac et al. showed a re-mixing of the drug and 
polymer as the sample is heated [7]. Interestingly, on the other hand, heat-induced 
crystallization has also been reported for itraconazole solid dispersions [22]. Solution 
calorimetry (SC) is another calorimetry technique that measures the thermodynamic 
10 
 
changes of a sample via a complete dissolution of the sample at a constant temperature. 
The first application of SC in the pharmaceutical arena that the authors are aware of was 
published approximately 40 years ago, where Pikal et al. utilized SC to determine the 
degree of crystallinity of β-lactam antibiotics [23]. To date, there have not been many 
published work on the use of SC, especially related to ASDs. Kayaert et al. used SC to 
measure the strength of interaction between two drug molecules and HPMC to elucidate 
the mechanism by which processing affects amorphization of nanocrystals [24]. Recently, 
Marsac et al. and Alin et al. employed SC to measure the interaction strength or mixing 
enthalpy between drug and polymer in ASDs [25, 26]. In SC, the heat of mixing is the 
difference between the heat of solution of the individual component and the weighted 
average of the components’ heat of solution in ASDs. The advantage of determining the 
mixing enthalpy by SC is that it captures the total intermolecular interaction including the 
strong hydrogen bonding interaction, which may not be accurately captured in solubility 
parameter calculation since only positive deviation is accounted for in this approach. 
Using Flory-Huggins calculation, the authors constructed a mixing free energy diagram 
from the measured mixing enthalpy as a function of composition, which allowed for drug 
solubility in polymer to be determined.  
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Table 1.1 List of analytical tools with their associated time scale and length scale or limit 
of detection (LOD) capability. 
 
DSC: differential scanning calorimetry, SC: solution calorimetry, PXRD: powder X-ray 
diffractometer, PDF: pair distribution function, IR: infrared, BCARS: broadband coherent 
Type Instrument Time scale (s) Length Scale/LOD 
Calorimetry DSC >100 [27] 20-30 nm [28]; 5 wt% [29] 
 SC  1 wt% [30] 
    
Spectroscopy PXRD/PDF  0.2-5 wt% [31] 
 IR  1-2 wt% [29] 
 Raman  0.05 wt% [27] 
 BCARS  300 nm [32] 
 ssNMR 10
-11-103 [33] 0.5-50 nm [34]; 0.3-1 wt% [35] 
 DEA 10
-11-104 [33, 36] 3-50 nm [37] 
 TSC 
25-3,000 [27]; 10³-
10⁴ [36] 1 wt% [30] 
 XPS  
20 µm (lateral); 10 nm (depth) 
[34]; 1 wt% [30] 
 EDS  
200 nm (lateral); 0.5-3 µm 
(depth); 0.1 wt% [38] 
 EELS  1 nm (lateral) [39] 
 ToF-SIMS  
50 nm (lateral); 1 nm (depth) 
[40] 
 AES  
7 nm (lateral); 0.02-20 nm 
(depth) [41] 
 SAXS  3-25 nm [33] 
 TPS  1-5 wt% [29] 
 DMA  2 wt% [42] 
 
SHG/Multi-
photon 
fluorescence  
90 nm [43] 
    
Microscopy/ 
Imaging (FIB) SEM  2 nm [39] 
 TEM  0.2 nm [44] 
 AFM  0.2 nm [45] 
 X-ray CT  1-4 µm [46] 
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anti-Stokes Raman scattering, ssNMR: solid-state nuclear magnetic resonance, DEA: 
dielectric analysis, TSC: thermally stimulated current, XPS: X-ray photoelectron 
spectroscopy, EDS: energy dispersive X-ray spectroscopy, EELS: electron energy loss 
spectroscopy, ToF-SIMS: time-of-flight secondary ion mass spectrometry, AES: Auger 
electron spectroscopy, SAXS: small angle X-ray scattering, TPS: Terahertz pulsed 
spectroscopy, DMA: dynamic mechanical analysis, FIB-SEM: focused ion beam 
scanning electron microscopy, TEM: transmission electron microscopy, AFM: atomic 
force microscopy, XR-CT: X-ray computed tomography, SHG: second harmonic 
generation.  
 
Spectroscopy involves any technique that captures the interaction between an 
electromagnetic radiation and an analyte. The majority of spectroscopy tools are 
nondestructive in nature, thus they lend themselves to characterize ASDs. PXRD, which 
is also known as wide angle X-ray scattering (WAXS), is an excellent technique to detect 
structural differences of the analytes as each analyte presents a unique diffractogram 
fingerprint. Constructive interference (Bragg intensity) can be observed due to the 
interaction between the X-ray incident beams with the long-range structure of crystalline 
analytes. This is contrary to the interaction with amorphous materials, which confers an 
amorphous halo or diffuse scattering instead. Quantifications as low as 5% (or less) of 
crystalline materials in an amorphous sample have been widely exemplified in the 
literature [20, 31, 47-49]. In addition, pair distribution function (PDF) can be applied to 
the resulting diffractogram of the ASD to evaluate its miscibility. PDF is a statistical 
method analogous to the Rietveld method [50], which is used to deconvolute component 
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composition from a diffractogram of crystalline mixtures while PDF is used to quantify 
individual component in an amorphous mixture [51]. A binary ASD is considered 
miscible if the PDF of the binary is unique from the weighted average of the PDFs of the 
individual components [49, 52]. Small angle X-ray scattering (SAXS) is another 
technique that utilizes X-ray beam and may be used to quantify differences in nanoscale 
density. The difference between SAXS and WAXS lies on the scattering angle where 
SAXS operates between 0.1-10° whereas WAXS between 10-90° 2θ angle. SAXS has 
been previously shown to elucidate nanoscale structures of pharmaceuticals [53]. 
Synchrotron, which uses a radially accelerated X-ray beam, may be used to generate yet a 
higher X-ray flux and an increased intensity compared to a regular WAXS or SAXS [54].  
Vibrational spectroscopy includes Raman and infrared (IR) spectroscopies. These 
techniques are capable to access vibrational transitions because the energy produced by 
these techniques corresponds to the vibration frequency, i.e. 1013-1014 Hz frequency. The 
ability of these techniques to detect crystallization and AAPS in an amorphous matrix has 
been previously reported [7, 8, 55-60]. Further, these techniques have been used to 
describe the impact of specific intermolecular interactions, e.g. hydrogen bond, on the 
mobility and stability of amorphous materials [61, 62]. The advantage of Raman over IR 
is that Raman operates with a stronger electromagnetic field and does not have significant 
water absorption. This is beneficial, as amorphous materials tend to be hygroscopic, thus 
the analysis by Raman does not require a correction for water that may be present in the 
samples. In addition, Coleman and Painter have utilized IR results to correct for hydrogen 
bonding interaction, which cannot be accounted for when using solubility parameter 
calculation, in the Flory-Huggins free energy of mixing calculation [63-65]. Broadband 
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coherent anti-Stokes Raman scattering (BCARS) is a nonlinear approach that has 
demonstrated significant enhancement in spatial resolution and speed compared to 
traditional Raman as a result of the use of multiple photons source [32]. Other nonlinear 
spectroscopy techniques, such as second harmonic generation (SHG) and multi-photon 
fluorescence, have also been explored recently in the pharmaceutical arena. Several 
authors have shown the utility of these nonlinear spectroscopy tools in detecting crystals 
in amorphous matrices [43, 66-68]. Terahertz pulsed spectroscopy (TPS) is a technique 
that operates in the far-IR region of the electromagnetic spectrum. The spectra produced 
by TPS relate to the intermolecular vibrations within the lattice structure instead of the 
intramolecular vibrations that are probed by FT-IR. Because amorphous materials lack 
the structural long-range order, they do not exhibit any spectral features, which makes 
TPS a sensitive tool to detect crystallization in amorphous solid matrix [69].  
Solid-state nuclear magnetic resonance (ssNMR) involves the excitation of NMR-
active molecules with non-zero spins nuclei using a high-powered radio frequency pulse 
in a static magnetic field [70]. Relaxation of the excited nuclei to the static magnetic field 
produces a free induction decay (FID), which can be transformed into the observed 
spectra using Fourier transform. ssNMR has been used to study the crystallization rate of 
several drug molecules via correlation with molecular mobility as measured by 1H NMR 
relaxation times [71, 72]. Yuan et al. observed distinct level of miscibility at select 
compositions of nifedipine-PVP dispersion using T1 and T1ρ relaxation time experiments 
[28]. It was found that compositions below 90% drug loading were miscible from the T1 
experiments but only miscible below 75% drug loading from T1ρ experiments. The 
authors concluded that the much smaller domain size of 2-5 nm captured by T1ρ 
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experiments provided a better nanoscopic view of the ASD compared to the 20-50 nm 
domain size obtained by T1 experiments, indicating that sensitivity of analytical tools or 
methods used dictates the information on ASD physical stability. Further, 2D correlation 
techniques can be utilized to determine the intermolecular interactions between different 
components in ASD necessary to form the “glass solution” [73]. For fluorine containing 
drug molecules, 19F NMR analysis provides higher sensitivity, which allows for a lower 
LOD and shorter acquisition time [74]. Dynamic mechanical analysis (DMA) exposes an 
analyte to mechanical stress at various frequencies and measures the resulting strain. 
DMA can be used to measure Tg of an amorphous system because there is a change in 
the storage and loss modulus around this transition point [75]. Several authors have also 
used this technique to study phase separation [75-78] as well as secondary relaxation 
processes in glasses [79]. Furthermore, Ediger et al. observed that relaxation times 
associated with thermodynamic variables, such as enthalpy or volume, correspond very 
well with those of mechanical variables, such as molecular rotation or viscosity, as shown 
in Figure 1.3 [33]. Dielectric analysis (DEA) operates analogously to that of DMA, 
except that the mechanical perturbation is replaced with an electrical perturbation. 
Numerous authors have shown the utility of DEA in detecting crystallization [80-88] and 
AAPS [89] in amorphous matrices. In addition, since it provides access to both local and 
secondary relaxations, DEA is found to be a very appealing approach to measure 
molecular motions in amorphous materials [33]. Thermally stimulated current (TSC) is 
another technique that uses electrical perturbation on the analyte. A TSC spectrum can be 
acquired by initially polarizing the sample with a static electrical field at a polarization 
temperature until the sample reaches equilibrium. The sample is then cooled down such 
16 
 
that the dielectric relaxation proceeds extremely slowly and the depolarization current 
due to the return to equilibrium temperature is recorded. The resulting TSC spectrum is 
complex but information from the distribution of relaxation times can be extracted 
through some fitting parameters. In addition, TSC can help us understand the local-order 
distribution in heterogeneous amorphous materials [90]. To date, TSC has been primarily 
utilized only in the polymer science field, but with its powerful capabilities, TSC could 
be an appealing tool in the pharmaceutical arena.  
 
 
 
Figure 1.3 Cartoon showing the log of the peak frequency νp as a function of inverse 
temperature for four samples: salol (□) and o-terphenyl mixed with 33% o-phenylphenol 
(○). The open symbols show dielectric relaxation data, and the corresponding solid 
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symbols show results from specific heat spectroscopy. Excellent agreement is observed 
between these two techniques. Adapted from Ediger et al. [33]. 
 
Surface analysis is also important for characterization of amorphous materials 
since surface properties may have an amplified effect on multiple measures of 
performance. In other words, particles located on the surface are the first ones exposed to 
potential interactions, such as mechanical stresses introduced during manufacturing 
processes and/or sorbed water from humid storage conditions. Sorbed water has been 
demonstrated to induce crystallization of amorphous materials [91-93]. Wu et al. have 
also shown faster crystallization kinetics at the surface, with rates of surface 
crystallization up to 150 times greater than the bulk crystallization rate [16]. In addition, 
localization of hydrophilic polymer on the surface will likely improve wettability 
required for dissolution process. X-ray photoelectron spectroscopy (XPS), where ionized 
atoms at the surface by the incident photons produces an ejected electron with a reduced 
energy, can be used to determine surface chemical composition. Dahlberg et al. have 
shown the utility of this technique and found that the rate of solvent removal and the 
solvent system by which ASDs are prepared could impact the surface heterogeneity, 
which in turn caused a different dissolution behavior across ASD tested [94]. Although 
the study by Dahlberg et al. demonstrated the great utility of XPS, applications in the 
pharmaceutical arena is still limited. With the abundance of studies showing surface 
associated failure mode, it is expected that the use of XPS or other surface 
characterization techniques will continue to rise. 
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Atomic force microscopy (AFM) is a high-resolution microscopy technique. As 
with any microscopy technique, AFM can directly observe phenomena occurring in the 
sample, such as crystallization and AAPS [7, 95-99]. However, if a crystal is observed, 
AFM does not have the discriminating power to determine the crystal polymorph. As 
such, AFM is often coupled with other technique, such as IR (AFM-IR). In addition, 
AFM-IR combination allows for detection of vibrational information at the nanoscale 
level, as opposed to the micrometer scale for conventional IR spectroscopy [100]. 
Focused ion beam scanning electron microscopy (FIB-SEM) is another microscopy 
technique that has recently been utilized to detect AAPS in a spray-dried felodipine-PVP 
dispersion [12]. The FIB provides the “cutting tool” to produce a thin slice on the spray-
dried particles, which is then followed by imaging via SEM at each cross section of the 
particles. Based on the SEM images of multiple sizes of particles, it was observed that 
porous particles were produced with particles >10 µm and AAPS was observed with 
particles >20 µm as contrast in the SEM images was present. The presence of AAPS was 
confirmed by electron dispersive X-ray spectrometer installed within the SEM that shows 
heterogeneity of chlorine content, which represents felodipine concentration in the 
particles. 
Other techniques include dynamic vapor sorption (DVS), inverse gas 
chromatography (IGC), and density measurement. DVS may provide information on 
amorphous content as amorphous materials tend to be hygroscopic [101]. Several studies 
have shown the utility of IGC to monitor the rapid surface crystallization event [14, 102]. 
Density measurement can be performed to quantify amorphous materials because these 
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materials exhibit a significantly lower density than crystalline materials. Pycnometry, 
either gas or liquid, is typically used for density measurement [20, 47].  
In summary, although by no means has this section captured all the available 
analytical tools, several commonly employed techniques and others that may perhaps be 
used more extensively in other fields than in the pharmaceutical arena are presented here. 
In addition, it needs to be stressed that no single technique can provide a holistic 
information of the glassy state, thus the use of an orthogonal approach is encouraged. As 
such, discretion should be employed by addressing the following questions: 
- What information (e.g. miscibility, crystallization rate, phase transition, etc.) is needed? 
- What detection/analytical tools are available? What information can these available 
tools provide? What are the limitations of the available techniques? 
- How much time is available for measurement?  
 
1.3 Bioperformance of ASD  
 When a solid dosage form are administered orally, the drug must undergo 
dissolution in the GI fluids and achieve a concentration sufficient for its absorption 
through the intestinal membrane. However, a combination of poor aqueous solubility and 
a high efficacious dose of the compounds in drug development pipelines lead to a high 
dose to volume ratio, i.e. a high dose number [103]. Herein, volume is defined as the 
theoretical liquid volume of 250 mL taken with administration of oral dosage form. The 
high dose number requires that formulations of such compound be designed in such a 
way that dissolution of the full dose occur within the timeframe of the GI transit. The 
enhancement in oral bioavaibility with the use of ASDs has been widely published [3, 
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104-106]. It is apparent that the superior bioperformance displayed by ASDs is due to the 
inherent free energy advantage of the amorphous drug over the crystalline state [107]. 
However, it has been reported that the use of ASD alone does not guarantee an improved 
bioperformance [3], thus several factors associated with the development of ASD need to 
be appropriately understood and will be discussed in this review. It is acknowledged that 
bioperformance is a complex process and other factors such as lack of biorelevance or in 
vivo predictability using current in vitro methods [108-110] as well as biological 
transporter/metabolism interplay [111, 112] could significantly alter ASD 
bioperformance. These topics, however, are out of the scope of this review and will not 
be discussed further here. Instead, the Bioperformance section of this review focuses on 
the physical chemistry mechanisms by which ASDs improve the bioperformance of the 
API and highlights recent modeling work on these mechanisms.  
 
Mechanisms for bioperformance enhancement by ASD: 
1. Supersaturation (solubility enhancement) 
2. Dissolution enhancement  
3. Permeability enhancement 
1.3.1 Supersaturation 
The equilibrium solubility of a crystalline drug is a solid-liquid equilibrium and is 
reached when the chemical potential of the solid crystalline drug (µ𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐) equals the 
chemical potential of drug molecules present in solution (µ𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠). In other words, the 
rate at which the crystalline solid dissolving is equal to that of crystallization from drug 
in solution; this is shown as Scenario A. Since majority of drug candidates exhibit very 
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low equilibrium solubility in water, one may add solubilizing excipients [113] to increase 
the drug concentration in solution. This addition of solubilizing excipients lowers 
µ𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 and allows more crystalline drug to dissolve. Although this solubilizing 
technique has been shown to increase drug oral bioavailability [114-116], readers should 
note that the use of solubilizing excipients may lead to undersaturation (Scenario B), 
which leads to decreased bioavailability. For instance, let us consider two formulations of 
the same drug at the same dose: formulation 1 containing drug suspension in water and 
formulation 2 containing a drug solution in a surfactant system such that the drug 
concentration is below its crystalline solubility. Although the total dissolved drug 
concentration is higher in formulation 2, the driving force for absorption (free drug 
concentration), µ𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠, is lower compared to that of formulation 1. An analogous 
scenario may also occur with food intake, which perhaps may explain negative food 
effect phenomena. Furthermore, supersaturation (Scenario C) is a state where the 
chemical potential of the drug in solution is higher than that of the crystalline solid (note 
that supersaturation occurs in the absence of the crystalline solid), which is the desired 
scenario for maximal ASD bioperformance.  
µ𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 = µ𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐             A. Equilibrium solubility (saturation) 
µ𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 < µ𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐     B. Undersaturation 
µ𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 > µ𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐     C. Supersaturation 
 
Although the use of chemical potential is a useful tool to understand the concept 
of supersaturation, it is difficult to measure the absolute value of a chemical potential. 
Thus, thermodynamic activity, which is a change in chemical potential with respect to a 
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standard state as shown in Eq. 1.1, is typically used instead. For simplicity of the 
discussion, the chemical potential of the crystalline drug dispersed in aqueous media at 
the crystalline solubility limit is used as the standard state. The extent of supersaturation 
can then be calculated by the activity ratio, 𝑎𝑎𝑅𝑅, as shown in Eq. 1.2. 𝑎𝑎𝑅𝑅 represents the 
ratio between drug thermodynamic activity at a given concentration in solution 
(𝑎𝑎𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠) to the activity at the crystalline solubility (𝑎𝑎𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠). In addition, each of 
the activity terms in both the numerator and denominator is a product of the activity 
coefficient (𝛾𝛾𝐷𝐷 ) and the drug concentration in solution (𝐶𝐶𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 or 𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐). 
Unfortunately, laboratory measurement of the activity coefficient is not straightforward. 
Hence, the extent of supersaturation is often calculated by supersaturation ratio (SR), 
which is the ratio of drug concentration in solution to the crystalline solubility as shown 
in Eq. 1.3, which neglects the activity coefficient terms [2]. While this approach may be 
valid to calculate supersaturation for certain conditions such as that in dilute solution, 
where 𝛾𝛾𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 
𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
≈ 1 as shown in Eq. 1.4, this assumption may not be valid in 
environments where solubilizing additives are present. Recently, Setiawan et al. has 
developed a practical approach to measure 𝑎𝑎𝑅𝑅 by utilizing diffusion cells as shown in 
Chapter 3. This approach was shown to effectively measure 𝑎𝑎𝑅𝑅 in systems containing 
solubilizing additives. 
𝑎𝑎𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 = 𝑒𝑒
µ𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠− µ𝐷𝐷
0
𝑅𝑅𝑅𝑅   where µ𝐷𝐷0 = µ𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐  [1.1] 
𝑎𝑎𝑅𝑅 ≡
𝑐𝑐𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑐𝑐𝐷𝐷,𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
= 𝛾𝛾𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 ∗  𝐶𝐶𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠 ∗ 𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
     [1.2] 
𝑆𝑆𝑎𝑎 = 𝐶𝐶𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
      [1.3] 
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𝑎𝑎𝑅𝑅 ≈ 𝑆𝑆𝑎𝑎 (
𝛾𝛾𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 
𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
≈ 1 for dilute solution)   [1.4] 
Supersaturation (µ𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠) can only be increased up to a certain limit, i.e. its 
amorphous solubility. In other words, the amorphous solubility is the highest absorption 
driving force that may be achieved when ASDs are employed [117]. This limit is also 
known as a critical aggregation concentration [118-120]. Hence, it is critical to 
quantitatively measure and predict the amorphous solubility of a drug candidate. 
Assuming that the crystallization rate is slow, continued addition of drug in a 
supersaturated solution will result in an amorphous drug phase separation from the drug 
in solution. At this point, the chemical potential of supersaturated drug in aqueous 
solution is equal to that of the water-saturated drug amorphous phase (µ𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 =
µ𝐷𝐷,𝑐𝑐𝑎𝑎𝑠𝑠𝑐𝑐𝑎𝑎ℎ𝑠𝑠𝑠𝑠𝑐𝑐). As noted previously, the absolute value of chemical potential is difficult to 
measure, thus the energetics advantage of the amorphous material over its crystalline 
counterpart may be calculated from the difference between the chemical potential of the 
amorphous and the crystalline materials. Hoffman initiated the development of equation 
describing this energetics advantage as shown in Eq. 1.5 [121]. Murdande et al. [122] 
recently extended this equation with correction for water activity and ionization as shown 
in Eq. 1.6. Note that it is quite challenging to produce a completely pure amorphous drug, 
since amorphous materials tend to be quite hygroscopic, thus a correction factor is 
necessary for a more accurate estimation of the amorphous solubility advantage over its 
crystalline counterpart. 
𝜇𝜇𝐷𝐷,𝑐𝑐𝑎𝑎𝑠𝑠𝑐𝑐𝑎𝑎ℎ𝑠𝑠𝑠𝑠𝑐𝑐−𝜇𝜇𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 = 𝛥𝛥𝐻𝐻𝑓𝑓 �
𝑇𝑇𝑚𝑚−𝑇𝑇
𝑇𝑇𝑚𝑚2
� 𝑇𝑇    [1.5] 
𝐶𝐶𝑐𝑐𝑎𝑎𝑠𝑠𝑐𝑐𝑎𝑎ℎ𝑠𝑠𝑠𝑠𝑐𝑐 = 𝐶𝐶𝑒𝑒𝑒𝑒 𝑥𝑥 𝑒𝑒
�𝜇𝜇2
𝑐𝑐−𝜇𝜇2
𝑐𝑐
𝑅𝑅𝑅𝑅 � 𝑥𝑥 𝑒𝑒[−𝐼𝐼(𝑐𝑐2)] 𝑥𝑥 �1−𝛼𝛼
𝑐𝑐
1−𝛼𝛼𝑐𝑐
�   [1.6] 
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where Ceq is crystalline solubility, 𝑒𝑒�
𝜇𝜇2
𝑐𝑐−𝜇𝜇2
𝑐𝑐
𝑅𝑅𝑅𝑅 � is free energy difference between the 
amorphous and crystalline forms and can be calculated using Hoffman approach in Eq. 
1.5, 𝑒𝑒[−𝐼𝐼(𝑐𝑐2)] is amorphous solute activity in solution, and �1−𝛼𝛼
𝑐𝑐
1−𝛼𝛼𝑐𝑐
� is ionized fraction of 
amorphous solute (αa) and of the crystalline solute (αc), 𝛥𝛥𝐻𝐻𝑓𝑓 is melting enthalpy of the 
crystalline drug, 𝑇𝑇𝑎𝑎 is melting temperature, and 𝑇𝑇 is temperature of measurement. 
 
From these equations, one needs to measure the crystalline solubility, melting 
point, melting enthalpy, water activity, and pKa (for ionizable compounds) to calculate 
amorphous solubility. Recently, Sadowski et al. [123] has developed a computational 
model utilizing perturbed-chain statistical associating fluid theory (PC-SAFT) that 
requires only few crystalline solubility data at different temperatures to estimate the 
amorphous solubility advantage. PC-SAFT treats organic molecules as a chain consisting 
spherical segments of a certain diameter with some fitted values from the experimentally 
determined crystalline solubility. The reported amorphous solubility for several drug 
compounds are in close agreement with the experimental values, which indicates that this 
approach may be beneficial in the early drug development pipeline where the amount of 
drug is quite limited.  
In vitro tools to assess supersaturation limit  
 Several methods for laboratory measurement of amorphous solubility have been 
reported. One approach is to dissolve amorphous material in water as shown on the left of 
Figure 1.4 [122]. The maximum drug concentration achieved is taken as the amorphous 
solubility. The challenge with this approach is that it is difficult to produce a completely 
pure amorphous material, which is free from crystallization and defect. Thus, the 
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concentration observed may not accurately represent the true amorphous solubility. 
Another approach is solvent or pH shift where the drug is dissolved in a solvent or 
different pH, respectively, and titrated into an aqueous environment until an amorphous 
phase separation is observed as shown on the right hand side of Figure 1.4 [124]. This 
approach, however, requires a sensitive detection method and an impedance of 
crystallization if the drug is a rapid crystallizer. Nevertheless, a summary by Taylor et al. 
shown in Figure 1.5 demonstrated that the predicted amorphous solubility are in good 
agreement with the experimentally measured values regardless of the method [117].  
 
 
     
Figure 1.4 Cartoons showing in vitro methods for amorphous solubility determination. 
(Left) Dissolution of freshly prepared amorphous drug (filled circle) compared to its 
crystalline form (filled diamond) as illustrated by Murdande et al. [122] Amorphous 
solubility value is signified by the peak of the dissolution profile. (Right) Titration of 
dissolved drug in an organic solvent into an aqueous media as illustrated by Ilevbare et al. 
[124]. Amorphous solubility value is signified by the rise in absorbance in the high UV or 
visible range. 
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Figure 1.5 Cartoons of correlation plot between measured amorphous solubility of 
different compounds in vitro and its predicted values as calculated by the Hoffman 
equation. Adapted from Taylor et al. [117] 
In vitro tools to assess the impact of excipients on supersaturation stability  
To assess the impact of excipients on the stability of drug supersaturation, which 
will be referred to as ‘parachute’ in the following section, a “top-down” approach can be 
utilized (Figure 1.6). This approach can be accomplished by either solvent-shift or pH-
shift methods. The goal is to dissolve the drug in a solvent or pH in which the drug is 
highly soluble then followed by a shift the media to an environment where the drug has a 
much lower solubility, thus creating a supersaturation state. Parachute effect due to 
excipients may be assessed by comparing the length of supersaturation to that in the 
absence of excipients. Various scales of volumes, from small (in the order of µL) to large 
(in the order of L), have been utilized depending on the available amount of the molecule 
tested [125, 126]. The length of supersaturation, which is also known as induction time, 
can be monitored by either measuring the drug concentration in solution or the formation 
of precipitate as a function of time. As precipitation is a kinetic process, it is best to use in 
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situ techniques that are capable of continuously monitoring drug supersaturation, such as 
UV dip probes [127, 128] or FBRM/PVM [129, 130]. While UV probes directly measure 
the drug concentration in solution, it may be difficult for these probes to distinguish UV 
absorbance of the dissolved drug from absorption and scattering due to particles formed 
when drug precipitation occurs. Second derivative technique may be used to eliminate 
this particle effect but submicron particles that scatter incident UV light may still obscure 
the concentration measurement [131-133]. Furthermore, FBRM/PVM technique may be 
used to directly observe the formation of particles in the media, but this technique is 
limited in that it does not provide any physicochemical properties of the formed particles 
besides particle size and morphology. Hence, FBRM/PVM technique is often coupled 
with a spectroscopy tool, such as Raman, IR, or near IR [130, 134, 135]. Ex-situ solid-
state analyses of precipitate particles have also been used as a means to complement the 
results observed in solution. Techniques, such as scanning electron/polarized light 
microscopy, differential scanning calorimetry, or powder X-ray diffraction, may 
accommodate an understanding of the parachute mechanisms brought about by excipients 
[128, 136]. 
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Figure 1.6 A “top-down” approach for evaluation of parachute effect from excipients.  
   
1.3.2 Dissolution enhancement 
The general dissolution process of ASDs follows the so-called “spring and 
parachute” concept [116]. ASDs contain a high-energy amorphous drug, which enable a 
rapid dissolution such that the intraluminal concentration reaches above the saturation 
solubility of the drug; this state is called the “spring.” For this strategy to be useful, the 
supersaturated solution must be stabilized for an adequate period to allow for significant 
absorption and thus enhance bioavailability. The stabilization of a supersaturated solution 
can be accomplished by adding precipitation inhibitors e.g. polymers, surfactants, which 
may act through a variety of mechanisms; this is called the “parachute.” Therefore, the 
success of ASDs depends on its ability to produce the spring and parachute effects.  
Dissolution phenomenon may be described by the Noyes-Whitney equation below 
𝑑𝑑𝑑𝑑
𝑑𝑑𝑐𝑐
= 𝑨𝑨∙𝐷𝐷
ℎ
(𝑪𝑪𝒔𝒔 − 𝐶𝐶𝑏𝑏)     [1.7] 
Here, X is the amount of dissolved drug, t is time, A is the surface area available 
for dissolution, D is the diffusion coefficient of the drug molecule, h is the thickness of 
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the boundary layer adjacent to the dissolving drug surface, Cs is the saturation solubility 
of the drug in a particular media, and Cb is the bulk drug concentration. Terms in bold 
indicate factors that may be modified by formulation approaches. ASDs typically 
demonstrate higher dissolution rate compared to crystalline API due to its higher 
solubility (i.e. amorphous solubility) [122, 124, 137] as indicated in the Supersaturation 
section above. ASDs will continue to dissolve until Cb is equal to Cs. Thus, the maximum 
achievable drug supersaturation in solution is the amorphous solubility where the 
amorphous drug in the ASD solid matrix is in “equilibrium” (assuming no crystallization 
occurs within the timeframe of GI transit) with the dissolved drug. Therefore, the 
amorphous-to-crystalline solubility, as discussed above, has a critical implication on 
bioperformance as this ratio dictates the extent of bioavailability enhancement possible 
by ASD. A wide range of amorphous-to-crystalline solubility ratios has been reported in 
the literature, e.g. 4 for ibuprofen and 65 for atazanavir [117, 138], indicating that 
formulating a drug as an amorphous product may not necessarily translate to the same 
bioavailability enhancement across different drug molecules. 
Often the mechanism by which ASDs dissolve is probed using an empirical 
approach where the explanation around the phenomenon is inferred from the observation 
of the API dissolution profile. To date, we are not aware of any mathematical model that 
adequately describes the dissolution process of multicomponent ASDs, suggesting that 
our current understanding of ASD dissolution is still limited. In addition, although it is 
recognized that ASDs are multicomponent in nature, research has been mainly focused 
on the drug dissolution profile. We believe that the success of ASDs in achieving the 
desired bioperformance may be predicted by understanding the multiple events that are 
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simultaneously occurring when ASDs are introduced into an aqueous environment. In a 
simple case of an ASD consisting of a drug and a polymer, multiple events including 
water ingress, polymer chain relaxation with volume expansion or swelling, drug 
diffusion, drug dissolution, and polymer dissolution may occur. Higuchi [139] initiated 
the work to interrogate the release behavior of a drug out of a solid matrix where drug 
diffusion is the main motive of release. Although Higuchi equation is simple and 
practical, it has many inherent assumptions and limitations such that caution should be 
exercised with the application of this approach. Examples of these limitations, among 
many, are that it assumes a thin film (not a three-dimensional release), it does not 
consider the effects of polymer swelling, and it assumes a fixed boundary layer, which 
may not be true if the polymer dissolution is accounted for. Recently, a more 
comprehensive mathematical model has been developed by Peppas and co-workers to 
describe the drug dissolution phenomenon [140]. Although originally developed for 
HPMC-based matrix tablets and water-soluble drugs, this new model was claimed to be 
valid for poorly water-soluble drugs and other HPMC type and derivatives including 
HPMCAS, which has emerged to be a commonly used polymer in ASD formulations.  
Thus, we believe that extending this equation to ASDs coupled with in situ 
characterization tools [129, 131] will aid in a better understanding of the ASD dissolution 
process.  
 
Formation of in-situ nanoparticles 
Another term that is critical to the dissolution rate is the surface area, A term in 
Eq. 1.7. Particle size is a key determinant to surface area. It has been well documented 
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that dissolution of ASD leads to the generation of nanoparticles and such size reduction 
may further accelerate the dissolution process. For instance, recently Harmon et al. 
reported the formation of anacetrapib nanoparticles as a result of fast dissolution of 
copovidone out of the ASD solid matrix [141]. Interestingly, the authors found that the 
size of nanoparticles, which ranges between 50-200 nm, varies depending on the 
surfactant concentration present in the ASD. Friesen et al. also observed drug/polymer 
colloid nanoaggregates of 20-300 nm size, which the authors claimed to rapidly exchange 
with the free drug in solution [142]. Nanoparticles of 200-500 nm size were also 
observed by Alonzo et al. following a dissolution of low drug loading ASD (90:10 
polymer/drug ratio) [133]. However, the authors observed that dissolution of high drug 
loading ASD (50:50 ratio) did not generate nanoparticles. The authors also noted that 
although the drug concentration generated by the two drug loadings was the same, the 
generation of nanoparticles with the low drug loading provided a faster dissolution rate. 
Other studies have also reported the generation of nanoparticles following ASD 
dissolution [22, 143-145], suggesting that formulators ought to be aware of this 
mechanism as another potential avenue to maximize ASD bioperformance. 
 
Speciation 
Another dimension of complexity in the dissolution of multicomponent ASDs is 
the potential formation of several drug species, such as dissolved/free drug, amorphous 
nanoparticles, micellized/complexed drug, and crystalline drug precipitates (Figure 1.7). 
Solution-state aggregates may be formed by both formulation excipients as well as by 
endogenous materials present in the body. Examples of these aggregates include micelles 
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created by surfactant above its critical micelle concentration [146, 147], aggregation of 
polymer with surfactant molecules to form “pearl-necklace shaped” aggregates [148, 
149], polymer gelling/colloidal formation [142, 150], vesicle or mixed micelle formation 
by different types of surfactant molecules [151-153]. Although extensive research on the 
solubilization of poorly water-soluble drug molecules by the aforementioned aggregates 
has been studied, knowledge on the impact of these aggregates on the supersaturated state 
is still meager. Qi et al. [149] showed some degree of swelling by these aggregates as 
well as a change in the micelle shape from spherical to cylindrical form when spray dried 
particles are dissolved, although it was difficult to assess from this study whether the 
resulting drug concentration corresponds to supersaturation. Indulkar et al. recently 
reported micelle swelling phenomenon at high supersaturation, suggesting that more drug 
molecules are packed into the micelles at high supersaturation [154]. Micelle 
solubilization at the supersaturated state is also discussed in Chapter 3, which uses 
estradiol and polysorbate 80 as model compounds. Furthermore, the kinetics of solute 
solubilization into micelles are very rapid, in the order of milliseconds [155, 156]. Thus, 
one could expect that the rate at which these aggregates replenish the free drug molecule 
is faster than that of the dissolution out of the ASD matrix, which is in the order of 
minutes [122, 133, 141]. Therefore, speciation induced by excipients may provide 
additional bioperformance advantage. 
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Figure 1.7 Illustration of various events experienced by an ASD formulation as it 
traverses through the GI tract prior to absorption to the systemic circulation.  
 
In vitro tools to assess extent of “spring and parachute” of ASD 
Given the importance of the attained supersaturation on the bioavailability 
enhancement, it is imperative that adequate in-vitro methodologies be designed to 
precisely measure the degree of supersaturation that are applicable for the prediction of 
in-vivo supersaturation. Dissolution experiments (‘bottom up’ approach in Figure 1.8) are 
usually performed to assess the extent of “spring and parachute” of ASD. Although USP 
type II dissolution apparatus has been traditionally used for dissolution measurements, 
Augustijns et al. pointed out a need for better harmonization among different institutions 
as well as a more biorelevant system for dissolution measurement [136]. The spring and 
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parachute may be monitored by either in situ measurement (e.g. UV probes) or ex situ 
(e.g. HPLC or NMR). Although the benefits of UV probes with online and less labor-
intensive measurements are obvious, HPLC may be coupled with various kinds of 
detectors, which may offer other critical benefits such as simultaneous quantification of 
excipients concentration. As discussed above, not only the dissolution of the drug but 
also that of the excipients need to be considered in order to obtain a holistic 
understanding of ASD bioperformance. Unfortunately, most of the commonly used 
excipients lack UV chromophore, thus UV probes or detectors alone are insufficient. 
Several detectors, such as refractive index (RI), evaporative light scattering detector 
(ELSD), and charged aerosol detector (CAD) are available for detection of these non UV-
absorbing compounds [157]. Therefore, utilization of these technologies needs to increase 
in the pharmaceutical arena.  
 
 
Figure 1.8 A “bottom-up” approach for evaluation of spring and parachute events from an 
ASD. 
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Impact of excipients on ASD dissolution 
Various polymers, such as PVP, PVP-VA, HPMC, and HPMC-AS have been 
evaluated for their impact on the extent of spring and parachute [133, 158-160]. These 
studies suggest that an amphiphilic polymer generally provides superior performance of 
an ASD. The polymer amphiphilicity advantage can be thought of a balance between 
rapid dissolution provided by the hydrophilic portion coupled with supersaturation 
maintenance provided by the hydrophobic portion [145, 161]. For instance, several 
authors [142, 162] observed a correlation between compounds log P and melting 
temperature with their associated dissolution and crystallization kinetics, respectively. 
These authors suggested that an amphiphilic polymer with a slightly more hydrophilic or 
hydrophobic property be selected to compensate for a slow dissolution rate or a fast 
crystallizer, respectively. Qian et al. [159] observed a rapid “escape” of PVP-VA in the 
dissolution profile of BMS-A/PVP-VA, which resulted in the rapid crystallization of 
BMS-A in the solid matrix and the subsequent poor BMS-A dissolution. On the other 
hand, despite slower drug dissolution, HPMC-AS was able to maintain drug 
supersaturation in solution for over 24 hours, which in turn resulted in an increased 
bioavailability. DiNunzio et al. conducted a study on the supersaturation maintenance 
ability as well as the dissolution behavior of itraconazole ASD using three different 
grades of HPMC-AS [163]. The authors observed that the HF grade, which is the most 
hydrophobic out of the three grades, showed a superior maintenance of itraconazole 
supersaturation. However, the most hydrophilic grade, i.e. LF grade, provided the highest 
oral bioavailability among the three grades due to its faster dissolution. These results 
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pointed out that polymer amphiphilicity could bring a significant influence on ASD 
bioperformance. 
Drug loading in the ASD matrix has also been shown to play an important role in 
the drug dissolution profile. Several reports [133, 143, 145, 164-168] have demonstrated 
drug-controlled and polymer-controlled regimes of dissolution at high and 
low/intermediate loading, respectively. Interestingly, in these studies, the drug dissolution 
rate at high drug loading is slower than that of low/intermediate drug loading. The 
proposed dissolution mechanism at low and intermediate drug loading is that the polymer 
dissolves rapidly which is then followed by drug dissolution into the viscous polymer-
rich layer, such that the release of the drug is dependent on the polymer release. The 
polymer-rich layer may also lower the drug thermodynamic activity of the drug, allowing 
for rapid dissolution of drug out of the ASD matrix. In contrast, at higher drug loadings, 
the hydrophobic drug molecules are more likely to dominate the surface of ASD and thus 
the dissolution rate may be controlled by the properties of the drug itself. Therefore, in 
the absence of a large surface area drug dissolution may be slow despite the amorphous 
character of the drug in the ASD matrix. 
 
1.3.3 Permeability enhancement 
Although different solution-state aggregates may be present in solution as 
described by the inset in Figure 1.7, the driving force for absorption is the molecularly 
dissolved drug, i.e. drug thermodynamic activity. Absorption across a membrane is 
described by Fick’s law (Eq. 1.8), where J is flux or mass transport per area per time, V is 
bulk volume, A is membrane surface area, Cb is bulk drug concentration (the same term 
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in Eq. 1.7), t is time, Peff (Eq. 1.9) is effective permeability, 𝑎𝑎 (Eq. 1.10) is drug 
thermodynamic activity, D is drug diffusion coefficient, K is membrane/water partition 
coefficient, h is membrane thickness, and γ is activity coefficient.  
𝐹𝐹𝑠𝑠𝑠𝑠𝑥𝑥(𝐽𝐽) ≡ 𝑉𝑉
𝐴𝐴
𝑑𝑑𝐶𝐶
𝑑𝑑𝑐𝑐
= 𝑷𝑷𝒆𝒆𝒆𝒆𝒆𝒆𝑥𝑥 𝒂𝒂     [1.8] 
𝑃𝑃𝑒𝑒𝑓𝑓𝑓𝑓 =
𝐷𝐷𝐷𝐷
ℎ
       [1.9] 
𝑎𝑎 = 𝛾𝛾𝐶𝐶𝑏𝑏       [1.10] 
As seen in Fick’s law above, flux can be enhanced by not only an increase in 
thermodynamic activity, which has been discussed in the Supersaturation section, but 
also by an increase in drug intestinal permeability. Effective drug permeability consists of 
both permeability through the unstirred water layer (UWL) and permeability through the 
epithelial cell membrane. Sugano [169] developed equations to describe the 
aforementioned permeability as shown in Eq. 1.11-1.14 below. 
1
𝑃𝑃𝑒𝑒𝑒𝑒𝑒𝑒
= � 1
𝑃𝑃𝑒𝑒𝑒𝑒
+ 1
𝑃𝑃𝑈𝑈𝑈𝑈𝑈𝑈
� 1
𝐹𝐹𝐹𝐹
     [1.11] 
log𝑃𝑃𝑒𝑒𝑎𝑎 = 1.1(log𝑃𝑃𝑠𝑠𝑐𝑐𝑐𝑐) − 5.63    [1.12] 
𝑃𝑃𝑈𝑈𝑈𝑈𝑈𝑈 =
𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒,𝑈𝑈𝑈𝑈𝑈𝑈
ℎ𝑒𝑒𝑒𝑒𝑒𝑒
+ 𝑃𝑃𝑤𝑤𝑐𝑐     [1.13] 
𝛾𝛾𝑒𝑒𝑓𝑓𝑓𝑓,𝑈𝑈𝑈𝑈𝑈𝑈 = 𝛾𝛾𝑎𝑎𝑠𝑠𝑠𝑠𝑠𝑠 · 𝑓𝑓𝑎𝑎𝑠𝑠𝑠𝑠𝑠𝑠 + 𝛾𝛾𝑏𝑏𝑎𝑎 · (1 − 𝑓𝑓𝑎𝑎𝑠𝑠𝑠𝑠𝑠𝑠)  [1.14] 
 
where Peff is the effective permeability, Pep is the epithelial cell membrane permeability, 
PUWL is the UWL permeability, FE is the surface area expansion coefficient of the fold 
structures in the small intestine, Poct is the drug octanol-water partition coefficient, 
Deff,UWL is the effective diffusion constant in UWL, heff is the effective thickness of UWL, 
and Pwc is the permeability coefficient by water convection,  Dmono is the diffusion 
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coefficients of unbound monomer molecules, Dbm is the diffusion coefficient of bile 
micelle-bound molecules in the UWL, and fmono is the fraction of free monomer. fmono can 
be calculated as the ratio of solubility in blank buffer (Sblank) and bile micelle media 
(Sdissolv) (fmono = Sblank/Sdissolv). Dmono can be calculated using Avdeef’s method [170].  
 
Epithelial permeability, Pep, of a drug is generally a function of its 
hydrophobicity, Poct, although the presence of permeation enhancers, including 
endogenous bile salt, may also increase epithelial permeability by the reversible process 
of intestinal cell abrasion and denudation [171-173]. UWL permeability, PUWL, is dictated 
by the Brownian motion of drug molecule in UWL. Nanoparticles, which may be formed 
during ASD dissolution, may diffuse into the UWL and decrease the heff, thus increasing 
the PUWL [174]. This phenomenon has been termed by Sugano as “particle drifting effect” 
[174].  
An example of the effect of nanoparticles on Peff is shown in Table 1.2. A 
hypothetical molecule with a molecular weight of 400, a logP of 4, FaSSIF solubility of 
10 µg/mL and aqueous solubility of 1 µg/mL was used for illustration. Using the 
equations shown above, the calculated Peff for this molecule is 1.70 x 10-4 cm/sec. As 
shown in the table below, depending on the dose administered the nanoparticles can 
provide significant enhancement in Peff for this molecule as compared to the original Peff.  
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Table 1.2 Hypothetical example of the effect of nanoparticle drifting on effective human 
permeability 
Dose (mg) 
% 
nanoparticles 
in formulation 
Effective dose 
in nanoparticles 
(mg) 
Particle size 
(nm, radius) 
Calculated Peff 
(x 10-4 cm/sec) 
10 70 7 50 1.73 
20 70 14 50 2.66 
50 70 35 50 4.98 
100 70 70 50 7.66 
 
Other studies have also demonstrated Peff enhancement due to nanoparticles. For 
example, Lenhardt et al. showed that nanoparticles increased the flux across Caco-2 
monolayers [175]. Frank et al. and Lian et al also showed enhanced permeation through 
Caco-2 monolayers due to nanoparticles generated from ASD dissolution [176, 177]. 
Further, Yildiz et al. showed that nanoparticles in the order of hundreds of nanometers 
are capable of diffusing through the mucus in in vitro studies [178]. In the same study, 
Yildiz et al. also demonstrated that particle size, surface chemistry, and intestinal 
contents have a significant impact on diffusivity through mucus, which constitutes as the 
major component in the intestinal membrane UWL.  
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In vitro/in vivo tools to assess drug permeability 
Several techniques available for the prediction and measurement of drug intestinal 
permeability include PAMPA or well plate with Caco-2 cells [170], diffusion cells 
(utilizing either synthetic membrane or excised tissue) [179-182], and in vivo perfusion 
[181, 183]. Avdeef [170] has shown a high correlation between Caco-2/PAMPA and 
human jejunal permeability (HJP) as shown in Figure 1.9, demonstrating the utility of 
these in vitro techniques. Although high correlation is observed, most of these studies 
were performed to measure the intrinsic drug permeability in the absence of excipients. 
Thus, it is intuitive to extend this work to systems containing potential excipients used in 
ASD and confirm the validity of these techniques in predicting intestinal permeability 
when excipients are present, especially at the supersaturated state. Recently, 
dissolution/permeation system (often called D/P system) has emerged as a tool to 
simulate the dissolution and permeation behaviors of a formulation simultaneously, 
which may serve as an additional bioperformance predictor in early drug development 
pipeline [184, 185]. 
 
Figure 1.9 Cartoons showing summary of in vitro and in vivo permeability (Pe) data of 
several compounds by Avdeef et al. [170]. (Left) Correlation plot between in vitro Caco-
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2 and in vivo human jejunal permeability (HJP) from compilation of Artursson’s 
laboratory at Uppsala University. (Right) Correlation between double-sink PAMPA and 
HJP developed by Avdeef. Double sink PAMPA utilizes pH 5.0 and 7.4 as donor and 
acceptor media, respectively. Pm is the Pe value with UWL correction. 
 
1.3.4 Physiologically based pharmacokinetic (PBPK) modeling for ASD 
The complex dissolution characteristic of ASD and the disparate mechanisms by 
which ASD enhances bioperformance makes it essential that the factors impacting their 
bioperformance be clearly understood. Therefore, it will be beneficial to expand the 
application of physiologically based absorption modeling to these formulations since 
modeling can be performed early in drug development process without consuming the 
limited amount of API at this stage. However, to date there are not many published 
reports available on simulation of absorption ASD in particular. While the principles of 
absorption from supersaturated solutions have been studied [186], publications on 
applications of such models during product development are very limited. Gao et al. 
[187] examined the prediction of ASD performance, among other formulations, for rat 
toxicology studies, while more recently Zheng et al. [188] discussed the utility of PBPK 
models in the discovery space to drive utilization of ASD. In addition, physiologically 
based absorption modeling to predict ASD bioperformance in human have been recently 
published by Mitra et al. [189]. The authors highlighted three cases: 1) ASD with 
complete absorption, 2) ASD with decreased fraction absorbed with dose escalation and 
3) ASD with incomplete and low absorption. These examples covered a wide spectrum of 
ASD bioperformance and strategies to model each of the case scenarios were discussed. 
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Thus, these examples demonstrated the utility of these models in providing early forecast 
of ASD bioperformance, which will provide mechanistic understanding of critical factors 
affecting ASD bioperformance and thereby aid the development of a drug product that 
will deliver the optimal benefit to patients. Furthermore, it is expected that the impact of 
speciation towards ASD bioperformance be part of future studies in PBPK modeling area 
to provide a holistic view of ASD absorption.  
 
1.4 Objectives 
 The overarching goal of this dissertation is to gain a molecular level 
understanding of factors affecting the drug thermodynamic activity in both the solid and 
solution state. In the solid state, a hypothesis around the relative impact of manufacturing 
and storage conditions on ASD bioperformance, i.e. drug activity, was tested. In the 
solution state, the hypotheses on how drug activity changes with speciation and the 
impact of this activity change on crystallization were evaluated. As such, the following 
specific aims were conducted to test these hypotheses: 
1. Perform literature survey to gauge the relative thermodynamics magnitude of each 
processes in which ASDs may be exposed to (Chapter 2) 
2. Evaluate the change in drug activity in solution in the presence of solubilizing 
excipient with the use of side-by-side diffusion cells (Chapter 3) 
3. Assess the impact of drug activity change resulted from the use of solubilizing 
excipient towards drug crystallization kinetics (Chapter 4) 
 
Copyright © Nico Setiawan 2018  
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Chapter 2 - The Amorphous Energy Landscape 
 
2.1 Introduction 
                Delivering poorly soluble active pharmaceutical ingredient (API) via the 
amorphous form may improve the kinetic drug solubility, dissolution rate, and oral 
bioavailability [20]. Although amorphous materials have a higher free energy compared 
to the associated crystalline form, little work has been done to understand the changes in 
chemical potential of the API throughout formulation and delivery processes.  
Specifically, the change in chemical potential resulting from mixing the API with 
polymer and in the presence of moisture at room temperature is particularly difficult to 
measure and, therefore, is largely unexplored with the exception of a few recent 
publications [26, 190, 191].  Further, API-polymer interactions and API chemical 
potential will be a function of the processing conditions (mechanical stress, exposure to 
various solvents, thermal stresses, etc.).  For instance, if an amorphous composite is 
produced via the spray drying process or via the co-precipitation process, it is important 
to understand the potential for formation of solvates as a function of solvent/co-solvent 
activities and or pH [192].  Alternatively, if an amorphous composite is produced via hot-
melt extrusion, the chemical potential as a function of temperature becomes an important 
aspect towards understanding phase behavior and the resulting impact on finished 
product [19].    
                In order to maintain the API in its amorphous state, typically excipients such as 
polymers are mixed with the drug to create an amorphous solid dispersion (ASD). ASDs 
have been shown to sustain the physical stability of the disordered API in the amorphous 
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composite when the glass transition temperature is well above the storage temperature 
[193] and when processing spaces do not provide kinetic access to failure modes such as 
crystallization [194] or amorphous-amorphous phase separation [195]. Thermody-
namically, the physical stability of ASDs is dictated by the miscibility and solubility 
limits. A system is said to be miscible when a mixture is homogeneous where the drug 
concentration is below the crystalline solubility limit or below spinodal decomposition 
limit. Between the spinode and the binode, amorphous-amorphous phase separation may 
occur via a process of nucleation of a discontinuous amorphous phase and a continuous 
amorphous phase. Practically speaking, producing an ASD in the thermodynamically 
stable region is ideal since in this region the API is truly “dissolved” in the polymer solid 
matrix. However, a high drug loading is often desired to reduce the manufacturing cost 
via increased throughput as well as to increase patient compliance, i.e. a smaller dosage 
form is desired. In addition, the performance of amorphous composites is a strong 
function of composition – some ASDs may gel when exposed to aqueous based media 
[141], some compounds may dissolve via different mechanisms as a function of 
composition [133, 145], and ultimately a change in bioavailability as a function of 
composition may occur [196]. The demand for high drug loading ASDs requires 
formulators to seek for ways to produce metastable ASDs that are stable during 
processing, storage, and GI transit. Ultimately, thermodynamic limits define the driving 
force for the observed kinetic processes. This chapter provides a summary of literature 
survey containing thermodynamic limits of each process experienced by ASDs and 
evaluate the relative thermodynamic values of each process.  
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2.2 Crystallization Energetics 
 As mentioned above, amorphous materials possess higher free energy than its 
crystalline counterpart does, which ultimately result in higher solubility and dissolution 
rate when the molecule is dissolved. In the same token, this high free energy places the 
molecules in a metastable state wherein the molecules possess some driving force for 
crystallization. For crystallization process to occur, molecules have to not only diffuse 
and coagulate but also be oriented such that the resulting orientation represents the crystal 
lattice. Due to the sluggish molecular diffusion in the glassy state [33] as well as the 
probability of achieving the correct orientation [197], crystallization rate may greatly 
vary depending on the experimental condition and the physicochemical properties of the 
molecule tested. Although the kinetics of crystallization is an important subject, this 
discussion will only focus on the thermodynamic factors affecting crystallization.   
 The calculation of crystallization driving force was initiated by Hoffman wherein 
the amorphous material is assumed to be a supercooled liquid at the temperature of 
interest [121]; this is shown in Eq. 2.1: 
𝛥𝛥𝛥𝛥𝑐𝑐−𝑐𝑐 = 𝛥𝛥𝐻𝐻𝑓𝑓 �
𝛥𝛥𝑇𝑇∙𝑇𝑇
𝑇𝑇𝑚𝑚2
�         [2.1] 
where ΔHf is the heat of fusion, ∆T = Tm – T, Tm is the melting point, and T is the 
measurement temperature.  
 
From this equation, it is clear that compounds with high heat of fusion will have a high 
crystallization free energy. This is exemplified in a study of hexitols crystallization 
conducted by Siniti et al. [198]. Eq. 2.1 has been shown to provide accurate prediction of 
the free energy change in small molecular weight organic molecules [199]. Hancock et al. 
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and, most recently, Sousa et al. followed up Hoffman’s work with heat capacity 
correction that provides a more accurate prediction of the crystallization free energy [137, 
138]. Note that free energy for crystallization is equivalent to the solubility advantage of 
amorphous materials over their crystalline counterpart (Section 2.5). Although the impact 
of enthalpy on crystallization is obvious, entropy effect is more difficult to assess. Zhou 
et al. observed that compounds with lower configurational entropy exhibit a faster 
crystallization process [197]. Configurational entropy can be assumed to be related to the 
number of assessable molecular conformations in the amorphous state and, thus, lower 
configurational entropy would result in higher probability to find the correct molecular 
orientation appropriate for the crystal lattice. However, this argument is counterintuitive 
when applied to the Gibbs free energy equation (𝛥𝛥𝛥𝛥 = 𝛥𝛥𝐻𝐻 − 𝑇𝑇𝛥𝛥𝑆𝑆) as both high enthalpy 
and entropy are required to result in high (crystallization) free energy, as opposed to 
having lower entropy. Hence, the entropy effect on crystallization may not be 
straightforward.  
 In an ASD, polymer interacts with API in such a way that there is a measurable 
solubility (𝛥𝛥𝛥𝛥𝑀𝑀 in Section 2.4) of API in the polymer. Although it has been shown that 
miscibility can be achieved in the absence of strong API-polymer interactions such as 
hydrogen bonding [200], it is likely that higher solubility or miscibility at higher drug 
loading is more achievable with systems exhibiting strong API-polymer interactions than 
those in the absence of significant interaction. In a hypothetical system with a strong 
API-polymer interaction, the chemical potential of the API is significantly lower 
compared to the neat amorphous API and the crystallization driving force is no longer 
represented by the calculated value in Eq. 2.1. Therefore, it is intuitive to select polymer 
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system that would offer significant intermolecular interactions with the API to increase 
the level of mixing as well as reduce the drug crystallization energetics. Further, the 
presence of water as either moisture in storage or bulk water in dissolution process may 
significantly alter this level of mixing. These topics will be discussed further in Section 
2.5.  
 
2.3 Relaxation Energetics 
 If we produce an amorphous solid by quenching from the molten state at a 
temperature just below the melting temperature, without crystallization of the amorphous 
solid, the molecular mobility is high enough for the system to remain equivalent. 
However, as the temperature drops near or below the glass transition temperature (Tg), 
the molecular motion becomes so sluggish that an amorphous solid is created containing 
higher free energy compared to the equilibrium supercooled liquid (Figure 2.1). Upon 
annealing at a certain temperature below Tg, glasses will continue to relax into a lower 
energy state with gradual loss of enthalpy and free volume. The enthalpy lost upon 
annealing can be recovered by reheating to reach the equilibrium supercooled liquid state, 
the amount of which can be measured by thermal analysis techniques such as differential 
scanning calorimetry [201, 202].  Relaxation of the amorphous material can have an 
impact on the crystallization through both the change in thermodynamic driving force and 
the kinetic effect due to loss of molecular mobility upon relaxation.  
The total enthalpy change that is required for the glass to relax to a supercooled 
liquid can be calculated by Eq. 2.2 [203]: 
∆𝐻𝐻∞ = ∆𝐶𝐶𝑎𝑎�𝑇𝑇𝑔𝑔 − 𝑇𝑇𝑐𝑐�        [2.2] 
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Among it, ∆Cp is the heat capacity difference between the glass and the supercooled 
liquid. Tg is the glass transition temperature, and Ta is the annealing temperature.  
 
 
 
Figure 2.1 Enthalpy vs temperature diagram for a typical polymer, in the amorphous and 
crystalline states. 
 
 ∆H∞ represents the theoretical highest recovery enthalpy that an amorphous glass 
can achieve at Ta. The relaxation kinetics of an amorphous material in the glassy state are 
non-linear in most of the pharmaceutical systems [201, 204] and expected to decrease 
with decreasing temperature and longer annealing time below Tg, which may sometimes 
make the measurement of the enthalpy of recovery challenging. ∆H∞ is used here for 
comparison, to estimate the maximum thermodynamic impact relaxation can have on the 
crystallization process.  
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Figure 2.2 Values of melting (blue) and maximum theoretical recovery (orange) enthalpy 
of various API. Percent value in parentheses represents the relative percent of theoretical 
maximum enthalpy recovery to the melting enthalpy. 
A survey of drug and drug-like compounds reveals that the theoretical maximum 
enthalpy of relaxation associated with neat amorphous materials ranges between 3-35 J/g 
at temperatures near room temperature (Figure 2.2). The enthalpy of relaxation counts for 
5-30% of the enthalpy of fusion in the systems included in the survey. After correction of 
the enthalpy of crystallization is corrected to the temperature of interest (annealing 
temperature of 298K in most cases, see table C.1), the enthalpy of relaxation could 
represent an even larger overall change in the energetics of the system. This observation 
suggests that during annealing, some amorphous solids, especially those with steep heat 
capacity change upon glass formation, may lose significant driving force for 
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crystallization upon relaxation. This loss of driving force, combined with the lower 
molecular mobility of a relaxed glass, can reduce the risk of crystallization by a large 
extent. It is worth noticing, however, that some of the high enthalpy of relaxation is 
rooted in the big difference between the glass transition temperature and the annealing 
temperature. The molecular mobility in these systems at the annealing temperature could 
be too slow for the pharmaceutical relevant time window, and the effect might not be as 
significant. For example, it has been experimentally demonstrated that molecular 
processes that occur in a drug at a temperature of at least 50 K lower than its glass 
transition temperature are too slow to be significant over the entire lifetime of a typical 
pharmaceutical product [201, 202]. It also needs to be pointed out that the systems 
compared above could be potentially biased towards moderate to slow crystallizers, as it 
is challenging to render a strong crystallizer to the amorphous state, to gather the 
enthalpy of relaxation data [205].  
 
Figure 2.3 Relaxation enthalpy of naproxen ASDs with different PVP polymers as a 
function of naproxen ratio in the ASD.  
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In the presence of polymer as additive, the enthalpy of relaxation is mostly 
increased, as the total enthalpy change for polymer is generally higher than that of the 
small molecule due to the larger difference between the glass transition temperature and 
the annealing temperature (Figure 2.3 and Table C.2). This suggests that the relaxation 
enthalpy of the API in the dispersion is miniscule compared to its own relaxation 
enthalpy as neat amorphous. The increase in the relaxation enthalpy is not likely the main 
reason for the improved physical stability of amorphous API in solid dispersion, 
however, as the increase is not very significant especially at high drug loading. It has 
been shown that even a small amount of polymer additive can effectively inhibit 
crystallization [206-208]. Further, a significant alteration in molecular mobility can also 
be observed when a small amount of polymer additive is added (Figure 2.4 and Table 
C.3). Valdecoxib and Etoricoxib solid dispersions with PVP K29/32 were annealed for 24 
hours, and recovery enthalpy was reduced with 1% of polymer addition and minimal Tg 
change.  
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Figure 2.4 Relaxation enthalpy of valdecoxib and etoricoxib ASDs with PVP K29/32 
polymer as a function of polymer ratio in the ASD.  
 
2.4 Mixing Energetics 
 Countless papers have been published with the aim of understanding the 
energetics of ASDs [209].  Sample preparation method must be taken into consideration 
when evaluating ASD energetics. Specifically, although it is understood that mixing 
requires favorable free energy of interactions, the phase behavior as a function of 
processing, e.g. spray drying or hot-melt extrusion, must be considered in that the number 
of phases in equilibrium will be a function of the temperature and composition. 
Application of thermodynamic principles requires an understanding of whether the 
system is kinetically trapped or truly miscible (Figure 2.5). 
 
0
1
2
3
4
5
6
7
8
9
0 5 10 15 20 25
∆H
re
l(
J/
g)
% Polymer in ASD
Valdecoxib-PVP K29/32
Etoricoxib-PVP K29/32
53 
 
 
Figure 2.5 Example temperature vs composition (left) and ternary (right) phase diagrams 
of polymer-API dispersions. 
 
Although improved physical stability of ASD compared to the neat amorphous 
API has been documented in the literature, the mechanism is not well understood [207, 
208, 210-220]. Assuming a single-phase ASD is achieved, there are some attempted 
explanations proposed in the literature for the improved physical stability. For example, it 
was proposed that in most cases, polymer has a higher Tg compared to the API, therefore 
the Tg of the amorphous solid dispersion would be elevated, and the molecular mobility 
needed for crystallization will be reduced. Alternatively, if the chemical potential of the 
API is lowered through mixing with a polymer, the crystallization driving force, and 
hence crystallization nucleation rate, will thereby be reduced (Figure 2.6). Furthermore, if 
favorable intermolecular interactions between API and polymer reduces the 
intermolecular distances, the resulting loss of free volume will also reduce mobility 
needed for crystallization. 
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Figure 2.6 Example energy diagram of an API-polymer dispersion and its pure 
components. 
 
Flory-Huggins lattice theory has been used as a good starting point to understand 
the thermodynamics of API-polymer systems with molecular size in consideration [221, 
222], as shown in Eq. 2.3.  
∆𝛥𝛥𝑀𝑀 = 𝑎𝑎𝑇𝑇�𝑠𝑠𝑑𝑑𝑐𝑐𝑠𝑠𝑔𝑔 lnΦ𝑑𝑑𝑐𝑐𝑠𝑠𝑔𝑔 + 𝑠𝑠𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐 lnΦ𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐 + 𝑠𝑠𝑑𝑑𝑐𝑐𝑠𝑠𝑔𝑔Φ𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐𝜒𝜒�  [2.3] 
Here, ndrug is the number of moles of drug, npolymer is the number of moles of polymer, 
Φdrug is the volume fraction of the drug, Φpolymer is the volume fraction of the polymer, R 
is the gas constant, and T is the absolute temperature. χ is the Flory-Huggins interaction 
parameter, which describes the enthalpy change of bonding a monomer unit with an API 
molecule. 
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The enthalpy of mixing for a drug-polymer binary system can be given by the van 
Laar expression in Eq. 2.4. 
∆𝐻𝐻𝑀𝑀 = 𝜒𝜒𝑎𝑎𝑇𝑇𝑠𝑠𝑑𝑑𝑐𝑐𝑠𝑠𝑔𝑔Φ𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐       [2.4] 
The Flory-Huggins interaction parameter χ is the determining factor in terms of enthalpy 
contribution to the free energy of mixing: a negative or slightly positive value of χ will be 
needed to lead to a negative value of free energy of mixing, and thereby facilitate mixing. 
On the other hand, a highly positive χ indicates strong cohesive interaction within drug or 
polymer, and therefore the mixtures are less likely to form a single-phased amorphous 
system. The χ value can be determined through model fitting of experimental data, for 
example gathered from melting-point depression measurements [221], solution 
calorimetry measurements or theoretical calculation [223]. Depending on the 
experimental method that is used to measure the miscibility between amorphous API and 
polymer, the χ value can vary. In Table 2.4, the χ value in addition to the enthalpy and 
free energy of mixing calculated based on χ are summarized. Fifty percent drug loading 
was used for the calculation as this usually corresponds to the highest degree of API-
polymer interaction.  It can be seen that when the χ value is small, the enthalpy of mixing 
is relatively insignificant compared to the enthalpy of fusion. When χ has a large negative 
value, which indicates strong adhesive interaction between API and polymer, the mixing 
enthalpy and free energy effects are on the other hand quite significant. Similarly, a large 
positive χ value renders a high positive free energy of mixing, indicating a poor mixing 
between API and polymer.  
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Table 2.1 Calculated enthalpy and free energy of mixing values based on given χ values 
when drug content is 50 vol-% in various drug-polymer systems. 
API Polymer χ ∆Hmix, J/g ∆Gmix, J/g ∆Hm, J/g 
Nifedipine PVPK12 -2.5 -6.6 -11.4 115.2 
Nifedipine VA64 -1.8 -4.7 -9.5 115.2 
Nifedipine PVAc 0.0 -0.1 -4.8 115.2 
Indomethacin PVPK12 -8.2 -28.9 -35.4 110.0 
Indomethacin PVPK25 -8.0 -28.2 -34.5 110.0 
Indomethacin VA64 -4.5 -15.8 -22.2 110.0 
Indomethacin PVAc -0.4 -1.4 -7.8 110.0 
Felodipine PVP K12 -0.1 -0.1 -2.9 80 
Nifedipine PVP K12 0.0 0.0 -2.9 115.2 
Ketoconazole PVP K12 -0.1 -0.1 -2.2  
Sucrose PVP K12 0.0 0.0 -3.2  
Indomethacin PVP K12 -0.8 -1.6 -4.6 110.0 
Sucrose Dextran 0.2 0.4 -3.9  
Ibuprofen Dextran 0.4 1.2 -4.6 130.0 
Indomethacin Dextran 0.7 1.4 -2.7 110.0 
Itraconazole Eudragit E100 0.1 0.1 -1.3 85 
Phenyl 
butazone 
PEG6000 0.1 0.1 -2.8  
Nifedipine PEG6000 0.1 0.1 -2.8 115.2 
Indomethacine PEG6000 0.4 0.7 -2.1 110.0 
Phenobarbital PEG6000 1.4 4.0 -0.1  
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Table 2.1 (continued) 
API Polymer χ ∆Hmix, J/g ∆Gmix, J/g ∆Hm, J/g 
Acetophenone PEG6000 0.4 2.2 -6.7  
Aspirin PEG6000 0.1 0.3 -5.1  
Paracetamol PEG6000 0.9 2.9 -1.5  
Phenyltoin PEG6000 0.6 1.8 -2.6  
Sucrose PEG6000 22.3 45.8 42.7  
 
Solution calorimetry is a very useful tool that can be used to directly measure the 
mixing energy in solid dispersion [224-226]. In the solution calorimetry method, a 
solvent that readily dissolves both drug and polymer serves as the thermodynamic 
reference state. A physical mixture of an amorphous drug and an amorphous polymer is 
dissolved into the specified solvent and the heat of solution is measured.  A single-phase 
solid dispersion of the same total composition as the physical mixture is then measured 
and the difference gives the heat of mixing the drug and the polymer. The enthalpy of 
mixing can hence be calculated with Eq. 2.5: 
∆𝐻𝐻𝑑𝑑𝑐𝑐𝑠𝑠𝑔𝑔−𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐 = �𝑥𝑥𝑑𝑑𝑐𝑐𝑠𝑠𝑔𝑔∆𝐻𝐻𝑑𝑑𝑐𝑐𝑠𝑠𝑔𝑔 + 𝑥𝑥𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐∆𝐻𝐻𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐� − ∆𝐻𝐻𝑑𝑑𝑠𝑠𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠  [2.5] 
The advantage of solution calorimetry is that it provides access to the activity 
coefficient at any composition and at the temperature of interest. In addition, enthalpy 
difference between amorphous and crystalline materials measured by solution 
calorimetry has been demonstrated to be more accurate than differential scanning 
calorimetry technique [227]. The solution calorimetry data presented here allows for 
calculation of the reduced chemical potential of the API through processing with a 
miscible polymer. Consider the magnitude of the heat of mixing of the compounds in 
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comparison to the heat of crystallization at room temperature. Generating these data 
across composition allows for direct measurement of the chemical potential. 
The energetics of mixing of diverse compounds, which are listed in Figure 2.7, 
are shown Figure 2.8 and as follows: itraconazole/eudragit system shows a near zero 
enthalpy of mixing, compound A/PVP-VA64 system shows a shallow heat of mixing and 
contains only dispersive interactions, compound B exhibits a weak hydrogen bond with 
HPMCAS, felodipine/PVP system displays a stronger interaction with a more negative 
mixing enthalpy, and indomethacin/PVP shows the most favorable mixing. The enthalpy 
of mixing in Figure 2.8 ranges from -3 to -40 J/g, which correlates well with the range 
seen in Table 2.1. Figure 2.9 further shows the free energy of mixing of these systems, 
which were obtained by combining the heat of mixing values shown in Figure 2.8 and the 
entropy contributions to mixing (i.e. -T*∆Smix) estimated from the Flory-Huggins 
equation (Eq. 2.2), as a function of polymer content. Furthermore, Figure 2.9 allows for 
calculation of API solubility in the amorphous polymer matrix by drawing a tangent line 
from the API heat of mixing curve to its corresponding polymorphic melting free energy, 
∆Ga-c, value (i.e. at 0% polymer). 
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Figure 2.7 Chemical structures of the compounds used in solution calorimetry analysis. 
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Figure 2.8 Enthalpy of mixing of several API-polymer model systems as a function of 
polymer content (%). Itraconazole/eudragit (brown), compound A/vinyl acetate-PVP 
copolymer (VA64) (pink), compound B/hypromellose acetate succinate (HPMCAS) 
(green), felodipine/PVP (blue), and indomethacin/PVP (red). 
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Figure 2.9 Free energy (∆G) of mixing of several API-polymer model systems as a 
function of polymer volume fraction calculated by estimating the entropic contribution to 
mixing (∆Smix) from the Flory-Huggins model. Free energy of crystallization values (∆Ga-
c) for the different crystal polymorphs of felodipine and indomethacin are shown as 
points on the y-axis. 
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As discussed in the previous section, an amorphous glass will relax to the 
equilibrium supercooled liquid line with annealing below Tg. In the solution calorimetry 
work performed by Marsac et al., the excess enthalpy of mixing which originates from 
relaxation was measured. The correction is shown for the indomethacin/PVP and 
felodipine/PVP systems.  In the case of the felodipine/PVP, the heat of mixing is 
significantly reduced from -6.7 J/g in the glassy state to -1.9 J/g in supercooled liquid at 
the 80:20 (drug:polymer) composition [227]. Alternatively, the measured heat of mixing 
of glassy indomethacin with PVP at the same 80:20 composition is -25.8 J/g while the 
calculated heat of mixing the supercooled liquids is -22.7 J/g.  The relaxation correction 
for these two particular systems is similar in magnitude but significantly different in their 
relative enthalpy change.   
In addition, the kinetics by which ASD approaches the equilibrium liquid line 
needs to be taken into consideration. Polymer additives tend to reduce the relaxation rate 
and the glass might not have the opportunity to relax fully within pharmaceutical relevant 
time frame.  For example, measured enthalpy of neat amorphous felodipine gives a value 
of about 6 J/g while enthalpy relaxation with addition of 10 wt% PVP gives a value of 
only 3 J/g [17]. Thus, it is reasonable to conclude that the impact of relaxation may be 
more significant at high drug loading. 
   
2.5 Impact of Water on ASD Energetics 
 The measurement of amorphous API solubility can be quite challenging due to its 
metastable nature. The ratio of amorphous to crystalline solubility (σamorphous/σcrystalline) 
can be written as the following [228, 229]: 
63 
 
𝜎𝜎𝑐𝑐𝑚𝑚𝑠𝑠𝑐𝑐𝑒𝑒ℎ𝑠𝑠𝑠𝑠𝑠𝑠
𝜎𝜎𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑒𝑒
= exp �∆𝐺𝐺𝑐𝑐−𝑐𝑐
𝑅𝑅𝑇𝑇
�       [2.6] 
where ∆Ga-c, the difference in the free energy of the crystalline and amorphous material at 
a temperature T can be estimated using the Hoffman equation in Eq. 2.1.   
As shown in Eq. 2.6, the free energy difference between the amorphous and 
crystalline API is directly related to the solubility difference between the two species. 
However, the measurement of amorphous API solubility is not straightforward especially 
when the API has a strong crystallization tendency [228]. Therefore, there may be some 
discrepancies shown in the experimental solubility ratio compared to the calculated value. 
Table 2.2 shows the experimental and theoretical amorphous-to-crystalline solubility 
ratios in literature. Most of the experimental solubility ratios are lower than their 
theoretical solubility prediction, due to the difficulty in measuring the amorphous 
solubility of compounds [228]. 
 
Table 2.2 Theoretical and experimental amorphous/crystalline solubility ratios of various 
drugs [124, 228], compared to their free energies of crystallization (∆Ga-c) at 25 °C, 
estimated by Eq. 2.6. 
Compound 
Experimental 
solubility ratio Theoretical solubility ratio T (°C) ∆ Ga-c, J/g 
Indomethacin 4.5 25-104 25 21.4, 23.5a 
Indomethacin 2.8 16-41 45 21.4, 23.5a 
Gibenclamide 14 112-1652 23 
 Glucose 24 16-53 20 
 Griseofulvin 1.4 38-441 21 
 Hydrochlorthiazide 1.1 21-113 37 
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Table 2.2 (continued) 
Compound 
Experimental 
solubility ratio Theoretical solubility ratio T (°C) ∆ Ga-c, J/g 
Iopanoic acid 3.7 12-19 37 
 Polythiazide 9.8 48-455 37 
 Felodipine 7-10 with polymer 9 37 16.2, 16.1, 16.3b 
Indomethacin 4.9 7 25 21.4, 23.5a 
Iopanoic acid 1.5 6 25 11.0 
Glipizide 9.2 11 25 21.8 
Glybenclamide 22.6 18 25 24.5 
Hydrochlorothiazide 4.9 33 25 35.3 
Terfenadine 10 13 25 19.9 
Griseofulvin 1.4 29 25 24.4 
Spironolactone 2.1 111 25 31.4 
Danazol 3 26 25 26.1 
Ritonavir 14.5 15.8 37 
 Efavirenz 2.2 2.4 37 
 Loratadine 4.8 4.3 37 
 Ketoconazole 14.7 15.3 37 
 Indomethacin 10.1 8.9 37 
 Felodipine 10.4 9.0 37 
 Clotrimazole 13.0 10.0 37 
 Clozapine 15.4 15.1 37 
 a Crystal form α and γ, respectively. Enthalpy difference of the indomethacin polymorphs 
obtained from: [137]. 
b Crystal form I, II and III, respectively. Differences in free energies between the 
felodipine polymorphs obtained from: [230]. 
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2.5.1 ASD Dissolution Energetics  
 Dissolution process is often described by the Nernst-Brunner equation below 
𝑑𝑑𝑀𝑀
𝑑𝑑𝑐𝑐
= 𝐷𝐷𝐴𝐴
ℎ
(𝐶𝐶𝑐𝑐 − 𝐶𝐶) ≈
𝐷𝐷𝐴𝐴𝐶𝐶𝑠𝑠
ℎ
       [2.7] 
M is the mass of solute dissolved, dM/dt is the dissolution rate, D is the diffusion 
coefficient of solute, A is the surface area of the exposed solid, h is the thickness of the 
diffusion layer, Cs is the solubility of solute in dissolution medium, and C is the 
concentration of solute in the dissolution medium. Under sink condition, C can be 
approximated to zero resulting in a simplified version of this equation. 
In this equation, the quantities of D and h are dictated by the physicochemical properties 
of the API as well as the anatomy and physiology of the absorption site, i.e. small 
intestine. This leaves surface area (A) and solubility (Cs) as variables controllable via 
formulation approaches. As discussed in Section 1.3.2, surface area can be increased by 
the generation of nanoparticles when ASD dissolve [133, 141, 159]. In addition, 
amorphous material possesses higher “solubility,” albeit it is a kinetic phenomenon, as a 
result of having a higher free energy than the crystalline counterpart. Hence, the 
amorphous solubility provides another means of enhancement in dissolution rate. 
Solubility of the amorphous material can be calculated by re-arranging Eq. 2.6 and 
adding correction factors for water activity and ionization constant proposed by 
Murdande et al. [122], as shown in Eq. 2.8 below: 
𝐶𝐶𝑐𝑐𝑎𝑎𝑠𝑠𝑐𝑐𝑎𝑎ℎ𝑠𝑠𝑠𝑠𝑐𝑐 = 𝐶𝐶𝑒𝑒𝑒𝑒 · 𝑒𝑒[−𝐼𝐼(𝑐𝑐2)] · 𝑒𝑒
�𝛥𝛥𝐺𝐺𝑐𝑐→𝑐𝑐𝑅𝑅𝑅𝑅 � · �1−𝑐𝑐
𝑐𝑐
1−𝑐𝑐𝑐𝑐
�     [2.8] 
Considering the fact that amorphous API chemical potential can be significantly 
reduced in an ASD, immense stability advantage in polymer can be achieved via 
increased API solubility especially when the magnitude of the free energy of 
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crystallization is comparable with the free energy of mixing. As seen in Table 2.2, the 
free energy of crystallization (∆Gc) for different compounds is similar in magnitude to the 
free energy of mixings of various drug-polymer disperisons (∆Gmix), shown in Table 2.1. 
For example, 50% indomethacin and 50% PVP shows a ∆Gmix of -35 J/g. This value is 
even lower than the reduction in chemical potential the pure indomethacin undergoes 
when crystallizing from the amorphous phase (-23.5 J/g, Table 2.2). Of course, an exact 
estimation of the thermodynamic stability enhancement can only be made by comparing 
the drug chemical potential in the dispersion to the one in the neat amorphous phase. 
Furthermore, solubility of drug in polymer at an arbitrary drug loading can be calculated 
by generating a ∆Gmix curve across the whole composition range (albeit the value of χ 
parameter may differ across composition) and solving for the chemical potentials by the 
graphical tangent intercept method as shown in Figure 2.9 [227].  
 For the thermodynamic aspects, consider a Flory-Huggins treatment of a binary 
amorphous API-polymer dispersion.  The reduction of the chemical potential of the API 
in this system (𝜇𝜇𝑑𝑑𝑠𝑠𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠,𝐴𝐴𝑃𝑃𝐼𝐼) relative to its pure amorphous form (𝜇𝜇𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼0 ) is given by 
[231] 
𝜇𝜇𝑑𝑑𝑠𝑠𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠,𝐴𝐴𝑃𝑃𝐼𝐼 − 𝜇𝜇𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼0 = 𝑎𝑎𝑇𝑇 �lnΦ𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼 + �1 −
1
𝐷𝐷𝑃𝑃
�Φ𝑐𝑐,𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐 + 𝜒𝜒Φ𝑐𝑐,𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐2 �  [2.9] 
where the Φ terms indicate volume fractions of respective compound in the amorphous 
phase and DP is the degree of polymerization.  For most polymers, DP is much larger 
than one, so this equation can be expressed approximately as 
𝜇𝜇𝑑𝑑𝑠𝑠𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠,𝐴𝐴𝑃𝑃𝐼𝐼 − 𝜇𝜇𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼0 = 𝑎𝑎𝑇𝑇�lnΦ𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼 + Φ𝑐𝑐,𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐 + 𝜒𝜒Φ𝑐𝑐,𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐2 �  [2.10] 
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At the amorphous solubility limit of the dispersion, the chemical potential of the API in 
the solution (𝜇𝜇𝑐𝑐𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼) is equal to the chemical potential of the API in the amorphous 
dispersion (𝜇𝜇𝑑𝑑𝑠𝑠𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠,𝐴𝐴𝑃𝑃𝐼𝐼), 
𝜇𝜇𝑐𝑐𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼 = 𝜇𝜇𝑑𝑑𝑠𝑠𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠,𝐴𝐴𝑃𝑃𝐼𝐼        [2.11] 
and accordingly, at the crystal solubility limit the chemical potential in the solution 
(𝜇𝜇𝑐𝑐𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼) would equal the one in the pure crystal phase (𝜇𝜇𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼0 ),   
𝜇𝜇𝑐𝑐𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼 = 𝜇𝜇𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼0          [2.12] 
The difference in the chemical potential of the API in the pure crystal phase relative to 
the one in the pure amorphous phase (𝜇𝜇𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼0 ), is 
𝜇𝜇𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼0 − 𝜇𝜇𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼0 = 𝛥𝛥𝛥𝛥𝑐𝑐−𝑐𝑐        [2.13] 
where 𝛥𝛥𝛥𝛥𝑐𝑐−𝑐𝑐 is the difference in free energy between the pure amorphous and pure 
crystalline API.  Eq. 2.10-2.13 can be combined to show the chemical potential 
difference between the amorphous solubility limit of the API in the dispersion, and the 
pure API crystal phase solubility limit: 
𝜇𝜇𝑐𝑐𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼 − 𝜇𝜇𝑐𝑐𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼 = ∆𝛥𝛥𝑐𝑐−𝑐𝑐 + 𝑎𝑎𝑇𝑇�lnΦ𝑐𝑐,𝐴𝐴𝑃𝑃𝐼𝐼 + Φ𝑐𝑐,𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐 + 𝜒𝜒Φ𝑐𝑐,𝑎𝑎𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑒𝑒𝑐𝑐2 �  [2.14] 
and so, the ratio of the activities of the two solutions at their respective limits (or the 
amorphous dispersion/crystal solubility ratio) becomes 
𝜎𝜎𝑐𝑐𝑚𝑚𝑠𝑠𝑐𝑐𝑒𝑒ℎ𝑠𝑠𝑠𝑠𝑠𝑠
𝜎𝜎𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑒𝑒
= 𝑒𝑒
∆𝐺𝐺𝑐𝑐−𝑐𝑐
𝑅𝑅𝑅𝑅 +lnΦ𝑐𝑐,𝐴𝐴𝐴𝐴𝐴𝐴+Φ𝑐𝑐,𝑒𝑒𝑠𝑠𝑠𝑠𝑐𝑐𝑚𝑚𝑒𝑒𝑐𝑐+𝜒𝜒Φ𝑐𝑐,𝑒𝑒𝑠𝑠𝑠𝑠𝑐𝑐𝑚𝑚𝑒𝑒𝑐𝑐
2
     [2.15] 
which can be compared to the solubility ratio in the pure amorphous form (Eq. 2.6), 
which contains only 𝛥𝛥𝛥𝛥𝑐𝑐−𝑐𝑐 in the exponent.  It can be seen in Eq. 2.15 that the more 
negative the value for χ is the more adhesive the API-polymer interactions are, and the 
lower the API loading in the dispersion is (lower ΦAPI) the greater is the reduction of the 
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amorphous solubility ratio by dispersion formulation.  For example an indomethacin-PVP 
dispersion (χ = -6.88 and ∆𝛥𝛥𝑐𝑐−𝑐𝑐= 7800 J/mol [227]) at a drug loading of 50%, gives an 
amorphous/crystalline solubility ratio of only 3.4 at 25 °C, as estimated by Eq. 2.15, 
while the solubility ratio in the pure amorphous form estimated by Eq. 2.6, is 23.  Since 
the crystal solubility is the same in both cases (pure crystal phase), this reduction of the 
ratio is due only to the reduction of the amorphous solubility of the dispersion.  By 
formulating an indomethacin-PVP dispersion, the amorphous solubility of indomethacin 
is hence reduced by a factor of almost 7. Therefore, although the stability of the API’s 
amorphous phase is improved by dispersing it in a polymer by reducing the kinetics of 
crystallization, the thermodynamic amorphous solubility might also be reduced. 
The above description covers a simplified case assuming that the solid 
immediately dissolves from the dry state into water, while the actual dissolution into 
aqueous media might be gradual.  Consider for example a case where an initially stable 
API-polymer dispersion gradually dissolves into water, where the solubility of API in 
water is very low.  This process could be illustrated in the phase diagram shown in Figure 
2.10.  The initially stable API-polymer dispersion is indicated by the black dot.  The 
dissolution of water into the dispersion could then follow the gradient outlined by the 
arrow. Because the miscibility between water and API is low, the chemical potential of 
the API in the dispersion would likely be increased as water is introduced into the system 
[232].  As the water content further increases the chemical potential of the API is also 
increasing, so that the composition is at some point found to be outside the region of 
stable composition (given by the crystalline solubility), which could cause crystallization 
at an early stage in the dispersion.  Further, as more water is absorbed, the mixture 
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crosses the spinodal line, which would cause amorphous phase separation before it would 
be diluted enough to remain outside the spinodal region (below the amorphous solubility 
limit) in the aqueous phase. 
 
Figure 2.10 Hypothetical ternary phase diagram of a miscible polymer-API system 
together with water, where water-API has limited miscibility. The arrow shows a route of 
increasing water content in the dispersion as it gradually dissolves into water. 
 
2.5.2 Impact of Water on the Activity Coefficient and Chemical Potential of the API 
in ASD 
The impact of water on ASDs, either storage moisture or dissolution process, can be 
described by Flory-Huggins model. The activity of a compound in a mixture or solution 
is defined as 𝑎𝑎 = 𝛾𝛾𝑥𝑥 = exp �𝜇𝜇−𝜇𝜇
0
𝑅𝑅𝑇𝑇
�, where γ is the compound’s activity coefficient, x is 
its molar fraction, µ is the chemical potential and µ0 is the chemical potential at the 
standard state. Flory-Huggins approach can be expanded to a mixture of API, water, and 
polymer to give the activity coefficient of the API [222, 232] in the dispersion:  
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ln 𝛾𝛾𝐴𝐴𝑃𝑃𝐼𝐼 = �ln
vAPI
𝑥𝑥𝐴𝐴𝐴𝐴𝐴𝐴
+ vpm −
vpm
DP
+ χAPI−pmvpm(1 − vAPI) + χAPI−H2OvH2O(1 − vAPI) −χpm−H2OvpmvH2O�
 [2.16] 
where xAPI is the molar fraction of API. As seen by the signs preceding each interaction 
term containing the χa-b parameters, unfavorable API-water miscibility (i.e. positive χAPI-
H2O) increases the activity coefficient and chemical potential of the API, while 
unfavorable polymer-water interaction (i.e. positive χpm-H2O) instead decreases the 
activity coefficient and chemical potential of the API in the mixture. Given the high 
hygroscopicity / hydrogen bonding potential of polymers that are often used as excipients 
or carriers in drug formulations (characterized by both a high Tg and a negative value for 
χpm-H2O), together with API’s poor aqueous solubility in general (positive χAPI-H2O), water 
will raise the chemical potential through both terms. Therefore, the chemical potential of 
the API in the dispersion could be raised with increasing water content when polymers 
with hydrogen bonding characteristics are used.  
 
2.6 Conclusion 
 Historical work has focused on theoretical and experimental approaches to 
understand individual processes that may lead to changes in the energy landscape of 
amorphous materials, but little work has focused on the relative magnitude of each 
process.  This paper has summarized and discussed the relative energy contributions from 
environmental storage (i.e. relaxation), formulation, and crystallization tendency in the 
amorphous phase, as well as stability of the amorphous form when the dispersion is 
exposed to moisture or introduced into aqueous media. 
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 Literature survey performed in this chapter revealed that relaxation can be 
significant, i.e. 5-30%, relative to the drug melting energetics. It was observed that the 
higher the change in heat capacity as glassy materials are formed the more significant the 
relaxation energetics will be. In addition, a significant change in the relaxation enthalpy 
was observed even with addition of small amount of polymers, indicating the importance 
of polymer addition in ASDs. It is more difficult, however, to compare relaxation 
enthalpy of the composite to the neat API melting energetics since the polymer 
significantly raises the relaxation enthalpy of ASD. Energy associated with mixing was 
found to be similar in magnitude as that of relaxation process. Further, the extent of 
mixing is strongly dependent on the χ parameter between the drug and the polymer used 
in an ASD. Mixing energetics could be significant when χ is large in magnitude, 
suggesting the importance of polymer selection in which mixing is highly favorable in 
such ASD. Amorphous drug-polymer dispersions not only reduce the mobility of the 
drug and drug crystallization kinetics, but also greatly reduce the chemical potential of 
the drug if the interactions between drug and polymer are favorable.  If the reduction in 
chemical potential by mixing with polymer is of the same order of magnitude as the free 
energy of crystallization at room temperature, an increased solubility and stability of drug 
in polymer can be obtained. On the other hand, the presence of water in the dispersion, 
either storage moisture or GI aqueous environment, will increase the chemical potential 
of the drug. Furthermore, drug chemical potential could be further inflated by the 
potential polymer-water interaction. Understanding the favorability extent of drug-
polymer interaction will aid formulators in deciding the drug loading in ASDs, where 
higher drug loading can be utilized for a more favorable drug-polymer combination. 
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Overall, generation of a complete thermodynamic description of an ASD is possible and 
critical to the success of ASD performance.  
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Chapter 3 - What is the True Driving Force for Absorption of Poorly Water-Soluble 
Drugs in the Presence of Solubilizing Additives? 
 
3.1 Introduction 
 Research shows that approximately 70% of new chemical entities may be 
classified as Biopharmaceutics Classification System (BCS) Class II compounds, which 
have low solubility and high permeability characteristics in its most stable crystalline 
form [107, 233, 234]. When delivered orally, drug molecules must first dissolve in the 
gastrointestinal (GI) environment in order for permeation and absorption to occur. 
Consequently, drugs with poor aqueous solubility and/or low dissolution rate have 
minimal driving force for absorption. Supersaturating drug delivery systems (SDDS) [2], 
such as amorphous solid dispersions (ASDs) [3, 235], have been demonstrated to 
promote absorption of poorly soluble compounds. The use of SDDS leads to a generation 
of drug supersaturation whereby the drug free energy is higher than that of the crystalline 
state, resulting in an increased driving force for absorption.  
 In vivo absorption phenomenon is often simulated in vitro by diffusion cells and 
mathematically described by Fick’s law (Eq. 3.1). The rate of absorption per unit area, 
represented as flux (J), is a product of the effective permeability (Peff) and the drug 
solution thermodynamic activity (𝑎𝑎𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠). Experimentally, volume (V) and 
membrane surface area (A) along with the change in drug concentration as a function of 
time in the acceptor (𝑑𝑑𝐶𝐶
𝑑𝑑𝑐𝑐
) terms can be measured to determine the flux across a membrane.  
𝐹𝐹𝑠𝑠𝑠𝑠𝑥𝑥(𝐽𝐽) ≡ 𝑉𝑉
𝐴𝐴
𝑑𝑑𝐶𝐶
𝑑𝑑𝑐𝑐
= 𝑃𝑃𝑒𝑒𝑓𝑓𝑓𝑓 ·  𝑎𝑎𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠    [3.1] 
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Peff is the effective permeability of the drug molecule through the unstirred water layer, 
which is dictated by the physicochemical properties of the drug molecule. Therefore, Peff 
is relatively constant as long as the drug is chemically stable, and the extent of absorption 
is thus governed by the drug’s thermodynamic activity.  
Unfortunately, the measurement of thermodynamic activity is not straightforward 
and, thus, flux is often evaluated based on the bulk drug concentration in the donor side. 
While the use of bulk concentration may adequately estimate thermodynamic activity in 
certain conditions, such as dilute or ideal solution, the application of this assumption to 
describe in vivo absorption could be erroneous because the drug concentration may not 
necessarily be dilute and that the total drug concentration may not represent the true 
absorption driving force [117]. For instance, drug molecules may be solubilized by 
endogenous surfactants present in the intestinal lumen and these molecules entrapped in 
the micelles may not readily be absorbed via passive diffusion, contrary to those ‘free’ 
molecules [179, 182]. In such non-ideal conditions, the effective concentration, i.e. 
thermodynamic activity, is a product of the drug concentration (𝐶𝐶𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠) and the 
thermodynamic activity coefficient (𝛾𝛾𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠) as shown in Eq. 3.2. Furthermore, non-
ideal flux (Eq. 3.3) can be calculated by combining Eq. 3.1 and Eq. 3.2. 
𝑎𝑎𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 = 𝛾𝛾𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 ∗  𝐶𝐶𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠   [3.2] 
𝐽𝐽 = 𝑃𝑃𝑒𝑒𝑓𝑓𝑓𝑓 ·  𝛾𝛾𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 ∗  𝐶𝐶𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠   [3.3] 
Due to analogous reason of difficulty in thermodynamic activity measurement, 
supersaturation is often measured by supersaturation ratio (SR) in Eq. 3.4, which is a 
ratio between the total drug concentration, 𝐶𝐶𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠, and the crystalline solubility, 
𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 [2]. However, the total concentration may not be representative of the true 
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absorption driving force for the same reason noted above. Therefore, the true extent of 
supersaturation should be calculated as the activity ratio (𝒂𝒂𝑹𝑹), which is a ratio between 
the drug solution activity, 𝑎𝑎𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠, to the drug solution activity at the crystalline 
solubility limit, 𝑎𝑎𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠, as shown in Eq. 3.5. The drug solution activity coefficient 
and the drug solution activity coefficient at the crystalline solubility are represented as 
𝛾𝛾𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 and 𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐, respectively. Note that the 
𝛾𝛾𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 
𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
 term in Eq. 3.5 serves as 
the correction factor for supersaturation in non-ideal conditions. Furthermore, Eq. 3.5 can 
be combined with Eq. 3.1 to yield Eq. 3.6, which allows for calculation of 𝒂𝒂𝑹𝑹. In other 
words, flux at any non-dilute condition can be compared to the flux at the crystalline 
solubility in a surfactant-free system to attain the true extent of supersaturation. This 
approach assumes that the drug concentration at the crystalline solubility is dilute, which 
is applicable for most BCS class II compounds.  
𝑆𝑆𝑎𝑎 = 𝐶𝐶𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
        [3.4] 
𝑎𝑎𝑅𝑅 ≡
𝑐𝑐𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑐𝑐𝐷𝐷,𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
= 𝛾𝛾𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 ∗  𝐶𝐶𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠 ∗ 𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
= 𝛾𝛾𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 
𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
∗ 𝑆𝑆𝑎𝑎     [3.5] 
𝑎𝑎𝑅𝑅 ≡
𝑐𝑐𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑐𝑐𝐷𝐷,𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
= 𝐽𝐽𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑃𝑃𝑒𝑒𝑒𝑒𝑒𝑒
⁄
𝐽𝐽𝐷𝐷,𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑃𝑃𝑒𝑒𝑒𝑒𝑒𝑒⁄
= 𝐽𝐽𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝐽𝐽𝐷𝐷,𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
    [3.6] 
 
This paper aims to examine 𝒂𝒂𝑹𝑹 and the ideality �
𝛾𝛾𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 
𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
� of estradiol (E2), a 
poorly water-soluble compound, in the absence and presence of a surfactant model. 
Furthermore, the loci of estradiol molecules, i.e. unbound or bound/micellized, will be 
determined in the presence of the surfactant based on the 𝒂𝒂𝑹𝑹 obtained. 
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3.2 Materials and Methods 
3.2.1 Materials 
17β-Estradiol (E2), polysorbate 80 (PS80), and tris maleate were purchased from 
Sigma-Aldrich (St. Louis, MO). Sodium hydroxide, methanol, and dimethyl sulfoxide 
(DMSO) were purchased from Fisher Scientific (Fair Lawn, NJ). Hydroxypropyl 
methylcellulose (HPMC) K4M grade was obtained from Colorcon (West Point, PA). 
Deionized water was obtained from a MilliQ water purification device (Milli-Q 
Synthesis, Millipore, Bedford, MA) and filtered through a 0.22 μm filter (Millipak 40, 
Millipore, Bedford, MA) before use. Polytetrafluoroethylene (PTFE) syringe filters with 
a diameter of 13 mm (0.22 μm pore size) were purchased from Tisch Scientific (Cleves, 
OH). Regenerated cellulose dialysis membrane with 6-8 kDa MWCO was obtained from 
Spectrum Laboratories (Rancho Dominguez, CA). All materials were used as received. 
 
 
Figure 3.1 Chemical structures of estradiol (E2), polysorbate 80 (PS80), and 
hydroxypropyl methylcellulose (HPMC) 
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3.2.2 Crystalline Solubility Measurement 
 Crystalline solubility of E2 was determined by placing an excess amount of E2 
into a glass vial containing 50 mM tris maleate buffer at pH 7.4 in the absence and 
presence of excipients (for media containing excipients, excipients were pre-dissolved in 
the buffer prior to the solubility measurement). The mixture was rotated by a vial rotator 
in an incubator at 37°C for 72 hours, which was subsequently filtered through a 0.22 μm 
syringe filter. The syringe filter was saturated by discarding the first 3 mL of the filtrate. 
The concentration of E2 was determined by a high-performance liquid chromatography 
(HPLC) equipped with a UV detector (HPLC and UV detector by Waters, Milford, MA) 
and a Symmetry C18 column (4.6 mm internal diameter, 150 mm length, 5 μm particle 
size; Waters, Milford, MA). The mobile phase consisted of methanol and water in the 
ratio 70:30 v/v and was used isocratically. Detection wavelength was set at 280 nm. All 
solubility measurements were performed in triplicate. 
 
3.2.3 Flux Measurement 
 Flux experiments were performed using side-by-side diffusion cells (PermeGear, 
Inc., Hellertown, PA). A regenerated cellulose membrane (MWCO 6-8 kDa) was inserted 
between the donor and acceptor sides of each diffusion cells. The surface area of the 
exposed membrane was 7.065 cm2. Diffusion cells were stirred at 100 rpm and immersed 
in a water bath to keep a constant temperature of 37°C. The volume of solution was 30 
mL in each side of the diffusion cells. For experiments at SR=1 (i.e. suspension), the 
donor compartment was filled with buffer solution containing an excess of crystalline 
drug whereas the acceptor compartment was filled with a blank buffer solution. Drug 
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concentration in the acceptor compartment was monitored as a function of time to 
determine flux. The drug effective permeability can be calculated from this flux value 
using Eq. 5.1 and Peff was assumed constant throughout the rest of the flux experiments. 
For experiments at higher SR, a solvent shift approach was utilized, where a 
highly concentrated E2 solution in DMSO was transferred to the aqueous solution at t=0. 
DMSO content in the donor compartment was kept below 1% v/v. Experiments in the 
presence of surfactant was performed similarly as described above where suspension was 
used for SR=1 and solvent shift approach for higher SR experiments. The concentration 
of surfactant in the acceptor compartment was kept the same as that in the donor to avoid 
osmosis process. 
 
3.3 Results 
3.3.1 Crystalline Solubility  
The solubility of crystalline E2 in various media is shown in Figure 3.3. In the 
absence of excipients, E2 crystalline solubility was 2.2 ± 0.0 μg/mL in buffer. The 
addition of 1% w/v PS80 increased E2 crystalline solubility 30-fold to 60.2 ± 1.3 μg/mL. 
The addition of 100 μg/mL HPMC did not alter the crystalline solubility of E2 in either 
buffer or PS80 solution.  
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Figure 3.2 E2 crystalline solubility in different media. Error bars indicate standard 
deviation with n=3. 
 
3.3.2 JD,saturation, 𝑎𝑎𝑅𝑅, and 
𝛾𝛾𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 
𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
 in Buffer 
Based on Eq. 3.6, 𝐽𝐽𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 must first be determined to evaluate the true 
supersaturation, 𝒂𝒂𝑹𝑹. Figure 3.4 shows the acceptor E2 concentration versus time at the 
crystalline solubility limit, in which excess solids were added to exceed the E2 crystalline 
solubility value, in the buffer media. 𝐽𝐽𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 can be calculated by Eq. 3.1 with the 
slope of Figure 3.4 as 𝑑𝑑𝐶𝐶
𝑑𝑑𝑐𝑐
 term and the surface area and volume values are listed in 
Materials and Methods section. Thus, a value of 0.312 ug/cm^2/hr was obtained for 
𝐽𝐽𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠.  
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Figure 3.3 Acceptor E2 concentration versus time at the crystalline solubility limit.   
 
 Once 𝐽𝐽𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 is determined, 𝒂𝒂𝑹𝑹 can be determined by comparing the flux at 
any supersaturation level to 𝐽𝐽𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠. Herein, different degree of supersaturation was 
created on the basis of SR by multiplication of the equilibrium solubility, as noted in Eq. 
3.4. The resulting flux associated with each SR can then be compared to 𝐽𝐽𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 to 
determine 𝒂𝒂𝑹𝑹 via Eq. 3.6 and, subsequently, 
𝛾𝛾𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 
𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
 via Eq. 3.5. In the absence of 
surfactant (Figure 3.5), SR and 𝒂𝒂𝑹𝑹 correlate linearly and behave ideally with 
𝛾𝛾𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 
𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
≈
1 up to the maximum 𝒂𝒂𝑹𝑹 of 6. Above the maximum 𝒂𝒂𝑹𝑹, increase in SR did not further 
increase 𝒂𝒂𝑹𝑹 and, thus, 
𝛾𝛾𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 
𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
 decreases to satisfy Eq. 3.5.  
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Figure 3.4 Relationship between SR, 𝑎𝑎𝑅𝑅 (blue bar), and 
𝛾𝛾𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 
𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
 (orange circle, 
represented as ‘Gamma Ratio’) in buffer. Error bars represent standard deviation with 
n=3. 
 
3.3.3 𝑎𝑎𝑅𝑅 and 
𝛾𝛾𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 
𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
 in PS80 solutions 
 To illustrate the impact of PS80 surfactant on 𝐚𝐚𝐑𝐑, experiments with the same 
dissolved E2 amount of 20 μg/mL were performed in the buffer and two different 
concentrations of PS80 solution as shown in Figure 3.6. This figure shows that E2 
crystalline solubility increases while 𝐚𝐚𝐑𝐑 decreases with increasing PS80 concentration. At 
the highest PS80 concentration, 𝐚𝐚𝐑𝐑 was less than 1 indicating that the solution was no 
longer supersaturated. 
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Figure 3.5 𝑎𝑎𝑅𝑅 (blue bar) and crystalline solubility (orange square) in buffer, 0.1% PS80 
and 1% PS80 at the same E2 dissolved concentration. Error bars represent standard 
deviation with n=3.  
 
Although addition of 1% PS80 led to a subsaturated E2 solution at 20 μg/mL 
concentration, supersaturation can still be achieved by further increasing the initial E2 
concentration beyond its crystalline solubility limit of 60 μg/mL. Analogous to Figure 
3.5, 𝒂𝒂𝑹𝑹 and 
γD,solution 
γD,crystal
 values at different SR can be measured as shown in Figure 3.7. 
This figure shows that 𝒂𝒂𝑹𝑹 is higher than SR, especially for points before 𝒂𝒂𝑹𝑹 reaches the 
maximum. For instance, at SR=1, which is at the crystalline solubility, the flux is higher 
than that at the crystalline solubility in buffer. 𝒂𝒂𝑹𝑹 continues to increase with increasing 
SR up to the maximum 𝒂𝒂𝑹𝑹 of 6, which is the same to that in buffer. The values of 
γD,solution 
γD,crystal
 indicate that there is a positive deviation in the presence of PS80, which is 
followed by a decrease after maximum 𝒂𝒂𝑹𝑹 is achieved.   
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Figure 3.6 Relationship between SR, 𝑎𝑎𝑅𝑅 (blue bar), and 
𝛾𝛾𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 
𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
 (orange circle, 
represented as ‘Gamma Ratio’) in 1% PS80. Error bars represent standard deviation with 
n=3. 
 
3.4 Discussion 
 SDDS are an attractive approach to overcome poor aqueous solubility 
demonstrated by the majority of new chemical entities, owing to their ability to increase 
drug dissolution rate and generate high apparent solubility. Although supersaturation is 
not a new concept, the term supersaturation can be misleading. By definition, 
supersaturation is the increase in drug thermodynamic activity over that of the crystalline 
state, which is termed 𝒂𝒂𝑹𝑹 in this study. However, oftentimes it is difficult to directly 
measure thermodynamic activity in complex systems, such as when the drug is present in 
an environment with excipients and endogenous materials. Consequently, it is often more 
practical and convenient to define supersaturation as the ratio of total drug concentration 
over the crystalline solubility, i.e. SR. Herein, a mathematical approach was developed to 
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allow a rapid determination of 𝒂𝒂𝑹𝑹 by comparing the flux of any drug solution to its flux 
at the crystalline solubility in surfactant-free system, albeit that the crystalline solubility 
should be in the dilute region.  
Application of the derived mathematical equations on supersaturation in buffer is 
shown in Figure 3.5. A linear correlation between 𝒂𝒂𝑹𝑹 and SR was observed with 
γD,solution 
γD,crystal
 close to unity, which indicates that dilute or ideal condition assumed here is 
reasonably valid in buffer. At high SR, however, 𝒂𝒂𝑹𝑹 plateaus at a maximum value. The 
point at which 𝒂𝒂𝑹𝑹 reaches a plateau is also known as liquid-liquid phase separation or 
amorphous phase separation in the literature [124]. The measured E2 amorphous 
solubility in buffer was 14 μg/mL, which gives SR of 6, exactly where the 𝒂𝒂𝑹𝑹 plateau 
occurs (keep in mind that 𝒂𝒂𝑹𝑹 and SR correlate linearly at low SR).  Above this limit, 
there is no further increase in the true supersaturation and, thus, no increase in flux or 
absorption is observed. Subsequently, maintaining the drug concentration at this limit in 
the intestinal lumen throughout the duration of GI transit has been thought of as a 
strategy to maximize intestinal absorption [117]. 
The first comparison of 𝒂𝒂𝑹𝑹 in the buffer and PS80 solutions is shown in Figure 
3.6. This figure demonstrates that at the same total drug concentration, 𝒂𝒂𝑹𝑹 is considerably 
lower in PS80 solutions than in buffer. Although E2 may be in the supersaturated state in 
the surfactant-free system, addition of surfactant could cause a lower the degree of 
supersaturation to even an undersaturated state. This result suggests that the measure of 
performance of any dosage form, such as dissolution or flux, ought to be performed in 
simulated intestinal media containing bile salts and other potential formulation 
solubilizing agents. Such approach will then allow formulators to select an appropriate 
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dose that will generate a drug concentration that provides maximum driving force for 
absorption. The same practice could also be done in the presence of simulated food 
content to assess the potential negative food effect in drug absorption.  
In 1% PS80 solution, 𝒂𝒂𝑹𝑹 value is higher than SR for each SR point (Figure 3.7). 
For example, 𝒂𝒂𝑹𝑹 is almost 2 at SR=1, which suggests that supersaturation is observed 
even at the crystalline solubility limit in PS80 solution. This observation could potentially 
explain positive food phenomena. Similar to that in buffer, 𝒂𝒂𝑹𝑹 reaches a plateau at high 
SR, indicating that amorphous phase separation occurring between SR of 3 and 4. The 
measured E2 amorphous solubility in 1% PS80 was 220 μg/mL, which would give an SR 
of 3.7, confirming the observation in Figure 3.7. The values of γD,solution 
γD,crystal
 in this figure 
showed that there is a positive deviation from ideality, which indicates that the effective 
concentration (i.e. activity) is higher than the measured concentration.  
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Table 3.1 Summary of E2 thermodynamic activity, free drug concentration, and number 
of E2 molecules per micelle as a function of SR in 1% PS80 solution. Error values are 
standard deviation with n=3. 
 
SR 𝒂𝒂𝑹𝑹 
[Free Drug] 
(µg/mL) #Drug/#Micelle Km/w 
1 1.73 ± 0.03 3.80 1.6 14.8 
2 3.78 ± 0.17 8.31 3.2 13.4 
3 5.51 ± 0.37 12.11 4.8 13.9 
4 6.33 ± 0.48 13.92 5.9 14.8 
5 6.38 ± 0.60 14.04 5.9 14.7 
 
Furthermore, using the 𝒂𝒂𝑹𝑹 values found in Figure 3.7 combined with a mass 
balance of [𝐸𝐸2]𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑐𝑐 = [𝐸𝐸2]𝑓𝑓𝑐𝑐𝑒𝑒𝑒𝑒 + [𝐸𝐸2]𝑎𝑎𝑠𝑠𝑐𝑐𝑒𝑒𝑐𝑐𝑐𝑐𝑒𝑒, the free drug concentration, the Km/w, and 
the number of drug molecules per micelle can be calculated. Herein, the value of Km/w 
was found to be constant at approximately 14 at 1<SR<6 (Table 3.1). Assuming a 
constant PS80 aggregation number of 60 [236], the amount of E2 molecules contained in 
each PS80 micelle can further be calculated. As shown in Table 3.1, the number of E2 
molecules contained per PS80 micelle increases from approximately 1-2 E2 molecules at 
the crystalline solubility limit to six E2 molecules at the amorphous solubility limit (i.e. 
maximum 𝒂𝒂𝑹𝑹, indicating that micelles can sequester more drug molecules at the 
supersaturated state than that at the crystalline solubility limit. As more drug molecules 
are packed inside micelles, the size of these micelles increases. Others have also reported 
examples of “swollen” micelles as high as 2-3 fold increase in their hydrodynamic size at 
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the supersaturated state in surfactant-containing systems [149, 154]. Furthermore, the 
microenvironment of a micelle in which a solute may reside can be divided into two 
regions: hydrophobic core and palisade region, with the latter also known as the core-
corona interface [237]. Indulkar et al. observed that drug molecules mostly reside in the 
palisade region of micelles when the concentration is between the crystalline solubility 
limit and low levels of supersaturation, whereas at high supersaturation these drug 
molecules occupy both the core and palisade regions [154]. We suspect that the same 
phenomena is observed with E2 local environment at the supersaturated state where E2 
populates the palisade region at low supersaturation and both palisade and the core at 
high supersaturation.  
 
3.4.1 Pharmaceutical Implications 
 The mathematical equations developed in this study provided a rapid 
determination of 𝒂𝒂𝑹𝑹 and, thus, the absorption driving force. Although this technique was 
successfully applied to E2, which is a non-ionizable molecule within the gastrointestinal 
pH, application of this technique to other drug candidates requires a careful consideration 
on the membrane selection. A regenerated cellulose dialysis membrane was used in this 
study, which sufficed the need of separating free drug from both the amorphous 
aggregate and micellized drug molecules as previously demonstrated by others [154, 179, 
238]. However, we acknowledge that other drug molecules may very well have ionizable 
groups, may form dimers, or perhaps may be complexed with cyclodextrin, all of which 
would be “recognized” as a free drug species using the dialysis membrane. From the 
physiology standpoint of the oral absorption process, it is only the free neutral species 
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that drives the absorption across the intestinal membrane. Thus, in the more complex case 
described above, e.g. ionizable compounds, those that may form dimers, or cyclodextrin-
containing formulations, other membranes such as excised animal intestinal tissue or 
Ussing chamber [181] or those utilized in perfusion experiments [181, 183] among others 
should be employed and validated. In addition, the approach developed in this study 
requires a dilute condition, which can only be satisfied using poorly soluble compounds 
or BCS class II compounds. Nevertheless, the same approach of comparing the solution 
flux to the flux at the crystalline solubility in surfactant-free system as demonstrated in 
this study combined with an appropriate membrane selection based on the drug molecules 
tested would enable one to calculate the dynamic change in the drug thermodynamic 
activity necessary to maximize oral absorption.  
 
3.5 Conclusions 
 The use of solubilizing agents in a formulation can significantly alter the 
supersaturated state by changing the thermodynamic driving force for drug absorption. 
Herein, a comparison of flux of a drug solution to the flux at the crystalline solubility 
limit in surfactant-free system allowed for calculation of the true supersaturation, 𝒂𝒂𝑹𝑹. In 
addition, this approach enabled the mechanism elucidation by which surfactant micelles 
modulate supersaturation, whereby there is an increase of E2 molecules contained per 
micelle from approximately two molecules at the crystalline solubility limit to six 
molecules at the amorphous solubility limit. The exercise performed here is a useful 
approach to determine the true driving force for absorption in complex systems 
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containing various solubilizing excipients without prior knowledge of the 
thermodynamics of the system itself. 
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Chapter 4 - Impact of Drug-Excipient Intermolecular Interactions on Estradiol 
Crystallization Kinetics  
 
4.1 Introduction 
 Although classical nucleation theory has been utilized to describe drug 
crystallization events arising from supersaturating drug delivery systems (SDDS) [2, 107, 
239, 240], often the crystallization processes, especially in complex systems where 
formulation excipients and endogenous materials are present during the gastrointestinal 
(GI) transit, are very stochastic in nature and hence difficult to predict. This challenge 
stems from the fact that the crystallization process is convoluted by both thermodynamic 
driving forces of the drug as well as kinetic effects from interactions between drug 
molecules and additives (either excipients or endogenous materials). The thermodynamic 
driving force for crystallization of an amorphous material is commonly described by the 
Hoffman equation [121] and the recent variation thereof with improved heat capacity 
correction [138]. This crystallization driving force is also the amorphous energetic 
advantage over the crystalline form for drug absorption across a membrane. Hence, the 
thermodynamic driving force is a “double-edged sword” where a high driving force 
results in high absorption rate with a high crystallization risk.  
For drug delivery purposes, excipients are added to minimize the high 
crystallization risk while still maintaining a high absorption rate. The use of excipients in 
SDDS has been ubiquitously illustrated in the literature, but the results observed may not 
necessarily produce the desired crystallization inhibition effect. In fact, some excipients 
actually accelerate drug crystallization. In the case of surfactants, sodium dodecyl sulfate 
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(SDS) and dodecyl trimethyl ammonium bromide (DTAB) were found to maintain 
supersaturation of γ-aminobutyric acid by delaying nucleation [241]. Guzman et al. also 
showed the supersaturation maintenance of celecoxib by SDS, tocopherol polyethylene 
glycol 1000 succinate (TPGS), and cremophor EL among other surfactants tested in their 
formulation screening [116]. Another interesting study showed that bile salts, which are 
commonly found in the intestinal fluids, delayed the crystallization of several poorly 
soluble compounds tested [242]. On the other hand, celecoxib crystal growth was shown 
to be accelerated by SDS and TPGS [243]. In yet another example, carbamazepine 
crystallization was promoted by SDS and sodium taurocholate (STC) [244]. When 
studying polymer excipients, Chauhan et al. ranked polymers as PVP>Eudragit>HPMC 
for the inhibition of indomethacin crystallization [245] whereas the same types of 
polymers were ranked as HPMC>PVP>Eudragit for griseofulvin and danazol 
supersaturation [246]. Ilevbare et al. proposed that solubility parameter could be used as a 
predictive tool for drug-excipient compatibility, where polymers with similar solubility 
parameter to the drug would provide the longest induction time [127]. Although many of 
the systems analyzed in Ilevbare et al. study were observed to follow the solubility 
parameter criteria, there were deviations of this ‘rule’ observed. As seen in the examples 
above, observations around the impact of excipients on the supersaturated state tend to be 
valid case by case and are difficult to be generalized. In addition, formulation excipients 
are usually added not only for maintaining drug supersaturation but also for 
manufacturing purposes. Hence, despite the primary motivation for including a particular 
excipient, secondary effects might be realized. A seemingly infinite other combinations 
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of functional excipients might be added with various ends in mind but may lead to an 
impact on the kinetics of crystallization. 
As mentioned above, the observed induction time may be affected by the 
thermodynamic and kinetics factors, thus it is difficult to extrapolate the crystallization 
kinetics results to other systems. For instance, some excipients/additives, such as 
surfactants or bile salts, are capable of solubilizing hydrophobic drug molecules and 
could further change the drug thermodynamic activity in solution [154, 179, 247]. 
Therefore, it is difficult to distinguish whether a maintenance of supersaturation is due to 
a reduced thermodynamic activity caused by such solubilizing excipients or whether 
excipients provide a kinetic stabilization via drug-excipient intermolecular interactions. 
Previously, Setiawan et al. developed a mathematical model that allows for calculation of 
thermodynamic activity in the supersaturated state (Chapter 3). This chapter combines the 
mathematical model built in Chapter 3 with induction time experiments to probe the 
kinetics aspect of induction time due to excipients by keeping a constant thermodynamic 
activity. Specifically, this project aims to investigate the influence of hydroxypropyl 
methylcellulose (HPMC) and polysorbate 80 (PS80) on estradiol (E2) induction time.  
 
4.2 Materials and Methods 
4.2.1 Materials 
 17β-Estradiol (E2), polysorbate 80 (PS80) and tris maleate were purchased from 
Sigma-Aldrich (St. Louis, MO). Sodium hydroxide, methanol, and dimethyl sulfoxide 
(DMSO) were purchased from Fisher Scientific (Fair Lawn, NJ). Hydroxypropyl 
methylcellulose (HPMC) K4M grade was obtained from Colorcon (West Point, PA). 
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Deionized water was obtained from a MilliQ water purification device (Milli-Q 
Synthesis, Millipore, Bedford, MA) and filtered through a 0.22 μm filter (Millipak 40, 
Millipore, Bedford, MA) before use. Polytetrafluoroethylene (PTFE) syringe filters with 
a diameter of 13 mm (0.22 μm pore size) were purchased from Tisch Scientific (Cleves, 
OH).  Regenerated cellulose dialysis membranes with 6-8 kDa MWCO were obtained 
from Spectrum Laboratories (Rancho Dominguez, CA). All materials were used as 
received. The chemical structures of E2, PS80, and HPMC are shown in Figure 4.1.   
 
 
Figure 4.1 Chemical structures of estradiol (E2), polysorbate 80 (PS80), and 
hydroxypropyl methylcellulose (HPMC). 
 
4.2.2 Crystalline Solubility Determination 
 The equilibrium solubility values of E2 in various test media were determined by 
placing an excess amount of E2 solid powder into a glass vial with a PTFE-lined screw 
cap containing the appropriate media, e.g. 50 mM tris maleate buffer pH 7.4 or buffer 
containing excipient(s). The mixture was rotated by a vial rotator in an incubator at 37°C 
for 72 hours and then filtered through a 0.22 μm syringe filter. The syringe filter was 
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saturated by discarding the first 3 mL of the filtrate. The concentration of E2 was 
determined using high-performance liquid chromatography (HPLC) with a UV detector 
(Waters, Milford, MA) and a Symmetry C18 column (4.6 mm internal diameter, 150 mm 
length, 5 μm particle size; Waters, Milford, MA). The mobile phase consisted of 70:30 
methanol/water and was used isocratically. The detection wavelength was set at 280 nm. 
All solubility measurements were performed in triplicate.   
4.2.3 Amorphous Solubility Measurement 
 The amorphous solubility measurement was performed via a solvent shift method. 
Highly concentrated E2 stock solutions in DMSO were prepared and each of these 
solutions was added into a cuvette containing 3 mL solution of buffer in the absence and 
presence of excipients. The addition of E2 stock solution was repeated several times to 
obtain several points below and above the amorphous solubility. The final concentration 
of DMSO was less than 1% v/v. After each E2 stock solution addition, the solution was 
stirred at 300 rpm for at least 1-2 minutes before measurement using a UV-Vis 
spectrometer. UV-Vis absorption was monitored by a Shimadzu UV-1800 spectrometer 
(Columbia, MD) at a wavelength of 700 nm. The onset of the rise in UV absorbance was 
taken as the amorphous solubility point [124]. An aliquot of each solution was placed 
under polarized light microscope (Olympus, Waltham, MA) to confirm the absence of 
birefringence. 
4.2.4 Flux measurement 
 Flux experiments were carried out by following a method developed previously 
by Setiawan et al. (Chapter 3) to correct for the true extent of supersaturation, i.e. activity 
ratio (𝑎𝑎𝑅𝑅). Variables in Eq. 4.1 are bulk volume (𝑉𝑉), membrane surface area (𝐴𝐴), acceptor 
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concentration (𝐶𝐶), and effective permeability of drug molecules through the membrane 
(𝑃𝑃𝑒𝑒𝑓𝑓𝑓𝑓). Herein, 𝑎𝑎𝑅𝑅 is the ratio of the drug activity in solution (𝑎𝑎𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠) to the activity 
of the drug in solution at the crystalline solubility limit (𝑎𝑎𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠) as shown in Eq. 
4.2. Thermodynamic activity is a product of the drug activity coefficient (𝛾𝛾𝐷𝐷) and the 
corresponding solution concentration (𝐶𝐶𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠) or the crystalline solubility (𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐). 
Chemical potential of the crystalline solid drug dispersed in buffer at the saturation limit 
was used as the reference state for the activity measurement throughout this study. 
Supersaturation ratio (SR in Eq. 4.3) is a concentration-based measure of supersaturation 
where the ratio of the activity coefficients is neglected. Combination of Eq. 4.1 and 4.2 
provides a direct means to measure 𝑎𝑎𝑅𝑅 as shown in Eq. 4.4 where 𝑎𝑎𝑅𝑅 is a ratio of flux at 
any drug concentration (𝐽𝐽𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠) to the flux of drug at its crystalline solubility limit in 
surfactant-free system (𝐽𝐽𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠). 
𝐹𝐹𝑠𝑠𝑠𝑠𝑥𝑥(𝐽𝐽) ≡ 𝑉𝑉
𝐴𝐴
𝑑𝑑𝐶𝐶
𝑑𝑑𝑐𝑐
= 𝑃𝑃𝑒𝑒𝑓𝑓𝑓𝑓 ·  𝑎𝑎𝐷𝐷,𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠     [4.1]  
𝑎𝑎𝑅𝑅 ≡
𝑐𝑐𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑐𝑐𝐷𝐷,𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
= 𝛾𝛾𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 ∗  𝐶𝐶𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠 ∗ 𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
= 𝛾𝛾𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 
𝛾𝛾𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
∗ 𝑆𝑆𝑎𝑎  [4.2] 
𝑆𝑆𝑎𝑎 = 𝐶𝐶𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
        [4.3]  
𝑎𝑎𝑅𝑅 ≡
𝑐𝑐𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑐𝑐𝐷𝐷,𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
= 𝐽𝐽𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑃𝑃𝑒𝑒𝑒𝑒𝑒𝑒
⁄
𝐽𝐽𝐷𝐷,𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑃𝑃𝑒𝑒𝑒𝑒𝑒𝑒⁄
= 𝐽𝐽𝐷𝐷,𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝐽𝐽𝐷𝐷,𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
   [4.4]  
         
4.2.5 Induction Time Measurement  
 Desupersaturation of E2 was performed via a solvent shift method and analyzed 
by μDiss UV probes (Pion Inc., Billerica, MA). A highly concentrated stock solution of 
E2 was prepared in DMSO at varying concentrations depending on the initial 
supersaturation. A 100 μL Hamilton gas-tight syringe (Reno, NV) was used to inject the 
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drug stock solution into an experiment vial within approximately 20 s. The experiment 
vial was pre-filled with 20 mL of the corresponding media and stirred at 100 rpm. A 
thermal block was used to maintain a solution temperature of 37°C. A UV absorbance 
scan of E2 desupersaturation was generated and converted into its second derivative 
profile. The second derivative data at λ = 280 nm was then plotted against time as shown 
in Figure 4.2. Second derivative approach has previously been shown as a means to 
eliminate scattering effect from precipitate particles formed during a desupersaturation 
experiment, which in turn allows for a direct analysis of the drug concentration in 
solution [240, 248]. GraphPad Prism (La Jolla, CA) software was used to determine 
induction time from the second derivative data using the “plateau followed by one phase 
decay” model.  
 
 
Figure 4.2 Example of a typical second derivative of UV absorbance plotted as a function 
of time for determination of E2 induction time. Data points (triangle) are taken with 
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intervals of 30 s or 1 min. Solid line represents the Prism fitted curve to determine the 
induction time. 
 
4.2.6 Scanning Electron Microscopy (SEM) Analysis 
Morphology of the solid precipitates in each induction time experiment was 
triple-washed with 5 mL of cold water stored in a 4°C (this washing step was performed 
before all of the post induction time analysis) and then analyzed with an FEI Quanta 250 
Environmental SEM (FEI, Hillsboro, OR). Samples were mounted onto an aluminum 
stub using double-sided carbon tape. The sample surface was coated with a thin layer of 
gold/palladium using standard techniques. Micrographs were collected using a secondary 
electron detector and an accelerating beam voltage of 2 kV. 
 
4.2.7 Powder X-Ray Diffraction (PXRD) Analysis  
 Precipitate samples at the end of induction time were analyzed using a powder X-
ray diffractometer (Miniflex 600, Rigaku, The Woodlands, TX) at room temperature. X-
ray diffractograms were obtained by exposing the sample to Cu Kα radiation (40 kV, 15 
mA) with scanning speed of 2°2θ min-1 and step size of 0.02°2θ. 
 
4.2.8 Solid State Nuclear Magnetic Resonance (ssNMR) Analysis 
Room temperature ssNMR was acquired using a Tecmag Redstone spectrometer 
(Tecmag, Inc., Houston, TX) operating at 75.6 MHz for 13C (7.05 T static magnetic 
field). Samples were packed into 7.5 mm zirconia rotors and sealed with Teflon or Kel-F 
end caps (Revolution NMR, LLC, Fort Collins, CO). Experiments were performed using 
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a 7.5 mm double resonance MAS probe (Varian, Palo Alto, CA). All 13C spectra were 
acquired under MAS [249] at 4 kHz at ambient conditions.  13C chemical shifts are 
reported relative to 3-methylglutaric acid referenced to 18.84 ppm [250] with an accuracy 
of ±0.4 ppm.  13C spectra were collected using ramped-CP [251], TOSS [252], and 
SPINAL64 decoupling [253] with 1H decoupling field about 63 kHz. All spectra were 
acquired with a 5 s recycle delay and a 51.2 ms acquisition time. All spectra were 
processed without line broadening. 
 1H T1 relaxation values were measured using the saturation-recovery experiment 
through 13C observation. In the Fourier-transformed spectrum, the intensity of the peak of 
interest was plotted against recovery delay times and the values were fitted to the 
following equation within the TNMR software: 
𝑀𝑀 = 𝑀𝑀0 ∙ �1 − 𝑒𝑒
−𝜏𝜏 𝑇𝑇1� �      [4.5] 
where M is the integrated signal intensity and τ is the recovery delay time. M0 is an 
amplitude parameter obtained from the fit and T1 is the obtained spin-lattice relaxation 
time. 
 
4.3 Results 
4.3.1 Crystalline and Amorphous Solubility 
 Crystalline and amorphous solubility of E2 as a function of PS80 concentration 
are shown in Figure 4.3. In the absence of excipients, crystalline solubility is 2 μg/mL. 
This crystalline solubility value increases linearly with increasing PS80 concentration to 
60 μg/mL at 1% PS80. Addition of up to 0.05% HPMC (data not shown) did not affect 
the crystalline solubility in both the absence and presence of PS80. Amorphous solubility 
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measured at each PS80 concentration will be used to identify E2 concentrations that 
would provide the same 𝑎𝑎𝑅𝑅 of 6 at each PS80 level (recall from Chapter 3 that 𝑎𝑎𝑅𝑅=6 at 
the amorphous solubility limit regardless of the PS80 presence). Comparisons of 
induction time at 𝑎𝑎𝑅𝑅=6 is shown in Figure 4.5. 
 
Figure 4.3 E2 crystalline (circle) and amorphous (square) solubility as a function of PS80 
concentration. Error bars indicate standard deviation (n=3). 
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4.3.2 Induction Time 
 
Figure 4.4 E2 induction time in buffer, PS80 in both the absence and presence of HPMC 
at SR and 𝑎𝑎𝑅𝑅 of 3. The symbol “*” indicates induction time of longer than 12 hours. 
Number above each bar represents induction time in the presence of excipient(s) relative 
to that in buffer, 𝑐𝑐𝑠𝑠,𝑒𝑒
𝑐𝑐𝑠𝑠,0
. Each value represents the mean ± SD (n=3). CMC is critical micelle 
concentration. 
To illustrate the importance of correcting for the true extent of supersaturation 
(𝑎𝑎𝑅𝑅) in place of SR, induction time experiments were compared side by side at the same 
𝑎𝑎𝑅𝑅 and SR as shown in Figure 4.4. Relative induction time, 
𝒕𝒕𝒊𝒊,𝒆𝒆
𝒕𝒕𝒊𝒊,𝟎𝟎
, was used to indicate 
excipients impact on induction time as compared to the induction time in buffer. 
Induction time is accelerated by excipients when 𝒕𝒕𝒊𝒊,𝒆𝒆
𝒕𝒕𝒊𝒊,𝟎𝟎
< 1 and, conversely, delayed when 
𝒕𝒕𝒊𝒊,𝒆𝒆
𝒕𝒕𝒊𝒊,𝟎𝟎
> 1. Induction time of 25 minutes was observed in buffer at SR=3. At the same SR, 
𝒕𝒕𝒊𝒊,𝒆𝒆
𝒕𝒕𝒊𝒊,𝟎𝟎
 is equal to 0.15, 1.08, and 5.41 in low PS80 (below its critical micelle concentration, 
CMC, of 78 μg/mL), 1% PS80, and 1% PS80+0.01% HPMC systems, respectively. 
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When compared at the same 𝑎𝑎𝑅𝑅=3, 
𝒕𝒕𝒊𝒊,𝒆𝒆
𝒕𝒕𝒊𝒊,𝟎𝟎
 is equal to 0.15 in low PS80 system while it is 
greater than 21 in both 1% PS80 and 1% PS80+0.01% HPMC systems. Induction times 
in buffer and low PS80 system were equal at SR and 𝑎𝑎𝑅𝑅 of 3 because SR and 𝑎𝑎𝑅𝑅 were 
shown in Chapter 3 to correlate linearly in unity in the absence of solubilizing excipients 
or micelles. However, it is clearly demonstrated that induction time profile, especially in 
the presence of solubilizing excipients, differ significantly depending on whether SR or 
𝑎𝑎𝑅𝑅 comparison is used.  
 
 
Figure 4.5 E2 induction time as a function of PS80 and HPMC concentrations at 𝑎𝑎𝑅𝑅 of 6, 
which corresponds to the respective amorphous solubility limit. 
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Since the goal of this study was to isolate the kinetics factor of induction time, 
comparisons were done at the same 𝑎𝑎𝑅𝑅 to ensure that drug thermodynamic activity 
remains the same. Figure 4.5 shows a 3D plot of induction time as a function of excipient 
concentrations at aR=6, which corresponds to the maximum drug activity at the 
amorphous solubility limit (see Figure 4.3). Induction time was 15 minutes in buffer. 
Addition of HPMC, even at a low concentration, significantly prolongs induction time 
where E2 did not precipitate within the 4 hours of experiment. On the other hand, 
interestingly, the shortest induction time was observed in low PS80 system (below its 
CMC), consistent with observations in Figure 4.4. Induction time, however, increased 
with increasing PS80 concentration. At the highest PS80 concentration of 1%, induction 
time was 60 minutes. When HPMC is added, induction time was prolonged at each PS80 
concentration. In addition, Figure 4.5 suggests that there is an induction time maxima at 
each PS80 concentration, and the higher the PS80 concentration the less HPMC 
concentration is needed to reach this maxima. 
 
4.3.3 Characterizations of Solid Precipitates 
Solid precipitates generated at the conclusion of each induction time experiment 
were analyzed by several techniques to understand the mechanisms by which excipients 
affect induction time. Figure 4.6 shows the SEM images of solid precipitates generated at 
the end of induction time experiments in buffer, 1% PS80, and 1% PS80+0.01% HPMC. 
All precipitates from this study were crystalline in nature as confirmed by polarized light 
microscope (data not shown) and powder X-ray diffraction (Figure 4.7). Rod-shaped E2 
crystals were observed in precipitates from both buffer and 1% PS80+0.01% HPMC, 
103 
 
whereas irregular shape with mixtures of rod-like and plate-like crystal habits were 
observed in precipitates from 1%PS80. The X-ray diffractograms suggest that E2 
crystallized to its original hemihydrate crystal form in all media. Interestingly, 
precipitates from 1% PS80+0.01% HPMC exhibit a halo pattern in the 2-theta region 
between 35-45°, which suggests that there exists an amorphous co-precipitate in the 
collected sample.  
 
 
Figure 4.6 SEM images of solid precipitates obtained from (left to right): Buffer, 1% 
PS80, 1%PS80 + 0.01%HPMC. 
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Figure 4.7 Powder X-ray diffractograms of (from bottom up) as received E2, solid 
precipitates in 1%PS80 and 1%PS80 + 0.01%HPMC. 
To further investigate the precipitate sample from 1%PS80 + 0.01%HPMC, solid-
state NMR 1D scan was performed as shown in Figure 4.8. In addition, 1D NMR scan 
was performed on as received E2 and HPMC materials for comparison purposes. The 
precipitate sample showed broad peaks between 50-110 ppm region (indicated by arrows 
in the figure), which belong to HPMC. In addition, T1 relaxation times of E2 and HPMC 
in the precipitate sample were analyzed to investigate whether the two components are 
miscible in the sample [28]. The results in Table 4.1 showed that the T1 relaxation time of 
HPMC in the precipitate differs from that of E2 crystal, suggesting that the two 
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components are immiscible. Furthermore, the T1 value of HPMC in the precipitate 
sample is statistically different from the as-received HPMC, suggesting that there is some 
level of interaction between HPMC and E2 in the precipitate sample albeit they are 
immiscible. 
 
 
 
Figure 4.8 From bottom to top are the solid-state NMR 13C spectra of HPMC, as-received 
E2, and the solid precipitate obtained at the end of induction time experiment in 1%PS80 
+ 0.01%HPMC media. Arrows indicate the presence of HPMC molecules in the E2 solid 
precipitate.  
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Table 4.1 T1 relaxation times for E2 and HPMC in the precipitate sample and HPMC as 
received. 
Component T1 (s) 
E2 in precipitate >15 
HPMC in precipitate 3.16 ± 0.30 
HPMC as received 1.26 ± 0.02 
 
4.4 Discussion 
 SDDS rely on their ability to generate the ‘spring and parachute’ effect in the GI 
tract within the GI transit time to enhance the oral bioavailability of poorly soluble 
crystalline drugs [2]. The extent of ‘spring’ is key towards oral bioavailability 
enhancement where high ‘spring’ is needed to drive absorption, but low ‘spring’ is more 
favorable in maintaining supersaturation in general. Concentration-based SR has often 
been used to measure the extent of ‘spring’ term because of the practicality in laboratory 
measurement [2]. In a study conducted by Setiawan et al. in Chapter 3, however, 
demonstrated that SR could deviate from the true supersaturation, 𝑎𝑎𝑅𝑅. Therefore, 𝑎𝑎𝑅𝑅 was 
used in this study for induction time comparisons. Figure 4.4 illustrates the impact of the 
deviation between SR and 𝑎𝑎𝑅𝑅 on E2 induction time where the greatest disparity in 
induction time was observed especially in the non-dilute systems containing high PS80 
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concentration. These results suggest that while it is practical to use SR for induction time 
comparisons, significantly different results may be observed when 𝑎𝑎𝑅𝑅 is considered 
especially in systems containing solubilizing excipients. 
By means of comparing induction time at the same 𝑎𝑎𝑅𝑅, the impact of excipients 
(‘parachute’ term) on induction time kinetics can be evaluated. Figure 4.5 shows the 
impact of PS80 and HPMC concentrations on induction time at 𝑎𝑎𝑅𝑅=6. Low concentration 
of PS80 (below its CMC) was shown to accelerate induction time. Nucleation process is 
dictated by the sum total of competing free energy gain from creating a volume that 
creates a more stable state for the system and the free energy cost of creating an interface 
[254]. These nuclei undergo a reciprocating process of dissolution and crystallization 
until stable nuclei are formed, which is then followed by the subsequent crystal growth 
process. For every interface, a potential difference across the interface, which is also 
known as interfacial tension, is present. Interfacial tension is magnified when the degree 
of dissimilarity between the two species is high at the interface. Herein, hydrophobic E2 
nuclei are surrounded by hydrophilic aqueous environment, creating a high interfacial 
tension. Surfactant, abbreviated from ‘surface-active agent’, molecules tend to occupy 
these surfaces (liquid-gas) or interfaces (liquid-liquid or liquid-solid) and orient 
themselves in such a way that will reduce the surface/interfacial tension [255]. Hence, it 
is hypothesized that the short induction time in low PS80 system is due to the reduced 
interfacial tension, allowing a more facile transport of E2 molecules onto the nuclei. 
Although there is no direct evidence on this hypothesis, the surface tension data (not 
shown) suggest that there was a 40% reduction in the surface tension at the CMC of PS80 
compared to that in absence of PS80. Although surface tension (liquid-gas) is different 
108 
 
from interfacial tension (liquid-solid), it is reasonable to expect that a decrease in the 
surface tension be accompanied by a decrease in the interfacial tension. The 
hydrophilicity/hydrophobicity between the two interfaces, liquid-gas and liquid-solid, can 
be argued to be similar in nature. In addition, adsorption of surfactant molecules onto E2 
nuclei could also offer an explanation for the rapid E2 crystallization via ‘poisoned’ E2 
nuclei surfaces [256]. Based on the computational prediction of the E2 hemihydrate 
crystal structure, water molecules are shared between the hydroxyl groups attached to 
both benzene ring and the 5-membered ring of E2 molecule in a head-to-tail fashion 
[257]. Hence, if surfactant adsorption were to occur, hydrophobic tail of PS80 would 
have covered the hydrophobic face of E2 lattice and precipitate particles produced would 
have shown a uniform crystal habit. Instead, precipitates from PS80 solution exhibited 
random crystal habits, and thus surfactant adsorption may be ruled out or at least it may 
not be the primary factor for the short induction time observed.  
Above the CMC, surface tension remains constant. In other words, only the 
surfactant monomer brings about the change in surface tension. If interfacial tension were 
the primary factor for E2 induction time, then it is reasonable to expect that induction 
time be the same in PS80 systems both below and above the CMC. However, induction 
time is longer at higher PS80 concentration as observed in Figure 4.4 and 4.5. Although 
micelle adsorption could occur, the bulkiness (aggregation number of 60) of the PS80 
micelle along with its bulky PEGylated hydrophilic surface make it unlikely for PS80 
micelles to adsorb onto small E2 nuclei. In the presence of micelles, E2 molecules 
located in free aqueous environment and those in micelles are continuously exchanging. 
Thus, it is reasonable to observe a slower crystallization kinetic because this competing 
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effect would reduce the likelihood of free drug being available for nucleation, especially 
at low 𝑎𝑎𝑅𝑅 shown in Figure 4.4 where induction time in 1% PS80 is significantly longer 
than that in buffer. At higher 𝑎𝑎𝑅𝑅=6, induction time in 1% PS80 is shorter and close to the 
value observed in buffer (Figure 4.5). The fast crystallization at high 𝑎𝑎𝑅𝑅 could be due to 
micellar catalysis [258]. Micellar catalysis phenomena have been reported in the 
literature where a substrate is localized in the micelle such that the reactive site is 
available to the attacking reagent [259]. Nucleation is a physical reaction process, which 
could be catalyzed in micelles. At the amorphous solubility limit, there are 6 E2 
molecules contained per PS80 micelle as shown in Chapter 3. Therefore, it would be 
interesting to evaluate whether this number corresponds to the minimum number of 
molecules required to form a stable E2 nuclei to support micellar catalysis hypothesis.  
In all studies performed herein, the addition of HPMC always extends E2 
induction time. HPMC is known to increase the solution viscosity, which has been 
proposed as one of the mechanisms by which crystallization is delayed [260, 261]. 
However, our viscosity data (not shown) suggests that no significant change in viscosity 
is observed when HPMC is added, at least in the concentration range employed here. 
From the SEM data in Figure 4.6, needle-like crystal habits from 1% PS80+0.01% 
HPMC were observed. This needle-like habits is similar to that obtained from buffer but 
different from that obtained from 1% PS80 media, which has a random plate-like habits. 
Although similar in crystal habits, precipitates from buffer may differ in the lattice 
growing face compared to that in 1% PS80+0.01% HPMC. In other words, in buffer E2 
may grow on the fastest growing site along the hydroxyl terminal of the molecule 
whereas the presence of HPMC may block this site causing E2 to grow via a slower 
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growing site/axis. The fact that there is a change in crystal habits and a significantly 
longer induction time in 1% PS80+0.01% HPMC compared to 1% PS80 to suggests that 
there is an adsorption of HPMC on the surface of E2 precipitates. Indeed, this 
phenomenon is supported by the PXRD (Figure 4.7) and solid-state NMR (Figure 4.8) 
data, both of which showed the presence of HPMC in the precipitate samples. 
Quantitative analysis of HPMC in the precipitate sample using ssNMR was difficult due 
to the limited amount of sample generated and the long relaxation time of the E2 
crystalline. However, the precipitate sample was able to be quantitatively analyzed using 
charged aerosol detector HPLC system. The results suggest that the precipitate contained 
10% of HPMC. Although it is possible that the presence of HPMC in the precipitate is 
due to the residual water (since HPMC is pre-dissolved in the media) after filtration, this 
can be ruled out because analysis on the mass change between precipitate after filtration 
versus dried precipitate corresponds to less than 1% of water mass. If any of the HPMC 
from this residual water were “arrested” in the precipitate, its mass would have 
corresponded to less than 1 ppm mass of the sample (HPMC concentration was 100 
μg/mL in the media), which is miniscule compared to the 10% value observed in the 
HPLC data. Further, the fact that there is a significant change in T1 relaxation times 
(Table 4.1) between as-received HPMC and HPMC in the precipitate suggests that there 
is some degree of intermolecular interaction, such as surface adsorption, between HPMC 
and E2 molecules in the precipitate sample. A depletion experiment, where controlled 
size (0.4-22 μm) particles of E2 as-received crystals were dispersed in solution containing 
pre-dissolved HPMC, was also performed to identify whether HPMC adsorbs onto E2 
solid surfaces at the later portion of crystal growth step. The result showed that there was 
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no depletion of HPMC from the solution, which suggests that adsorption occurred at the 
early stage of nucleation when the nuclei size is in the low nanometers range or less. 
4.5 Conclusions 
Excipients, such as polymers and surfactants, are key components to successful 
supersaturated formulations as they are intended to provide the ‘parachute effect’ 
throughout the GI transit. However, the excipient screening process, which is typically 
performed in the pre-formulation step of the drug development, may often be performed 
at different thermodynamic activity and hence erroneous conclusions about the impact of 
excipients on induction time may be obtained. Coupling flux with induction time studies 
allows for measurement of crystallization kinetics at the same thermodynamic activity, 
which permits formulators to isolate the kinetics factor of induction time. This approach 
is a beneficial and useful application in excipient screening process, which provides 
information on the parachute effect while uncompromising the maximum spring effect. 
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APPENDIX A - Impact of Different Polymers on the Crystallization Kinetics of 
Structurally Diverse Drug Molecules 
 
A.1. Purpose 
 The purpose of this exercise was to observe the influence of different polymers on 
the induction time of several drug molecules.  
A.2. Methods 
 Induction time experiments were performed via a solvent shift method and 
analyzed by μDiss UV probes (Pion Inc., Billerica, MA). A highly concentrated drug 
stock solution was prepared in DMSO or methanol at varying concentrations depending 
on the initial supersaturation. A 100 μL Hamilton gas-tight syringe (Reno, NV) was used 
to inject the drug-in-organic solution into the experiment vial and the solution was 
injected within approximately 20 s. The experiment vial was pre-filled with 20 mL of the 
corresponding media and stirred at 100 rpm. Excipients of 100 µg/mL each were pre-
dissolved in the media. The vial was placed in a thermal block to maintain a solution 
temperature of 37°C. A UV absorbance scan of the drug was generated and converted 
into its second derivative profile. The second derivative data was then plotted against 
time to determine induction time. Amorphous solubility was determined following 
Ilevbare et al. method [124]. 
A.3. Results 
 Estradiol (E2) induction time data in Chapter 6 showed that, in general, E2 
crystallized quite rapidly and the addition of HPMC helped sustain supersaturation. It 
was then our interest to explore other commonly used polymers on E2 supersaturated 
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solution. All the experiments herein were performed at the drug amorphous solubility 
limit. Figures A.1 (top) and (bottom), which show E2 induction time in the absence and 
presence of 10 mg/mL PS80, respectively, suggest that there is no difference between the 
polymers used in maintaining E2 supersaturation, at least within the 2 hours experiment 
time. 
 
 
Figure A.1. E2 concentration profile as a function of time starting with supersaturation at 
the amorphous solubility limit of the drug in the absence (top) and presence (bottom) of 
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10 mg/mL PS80. Dotted line represents amorphous solubility limit and dashed line 
represents crystalline solubility limit. 
On the other hand, different polymers conferred very distinct induction time 
profiles when tested on other drug molecules, i.e. indomethacin and telaprevir, as shown 
in Figures A.2 and A.3. Interestingly, in some cases the concentration of indomethacin 
was able to exceed the amorphous solubility limit.  
 
Figure A.2. Indomethacin concentration profile as a function of time starting with 
supersaturation at the amorphous solubility of the drug in the presence of various 
polymers. Dotted line represents amorphous solubility limit and dashed line represents 
crystalline solubility limit.  
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Figure A.3. Telaprevir concentration profile as a function of time starting with 
supersaturation at the amorphous solubility of the drug in the presence of various 
polymers. Dotted line represents amorphous solubility limit and dashed line represents 
crystalline solubility limit.  
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APPENDIX B – Preformulation Screening of Structurally-Similar Abuse Deterrent 
Molecules  
 
B.1 Purpose 
 The purpose of this exercise was to determine several important parameters useful 
for preformulation screening process of structurally similar JPC molecules. JPC 
molecules were recently developed to treat methamphetamine abuse [262].  
B.2. Methods 
 Solid-state crystallization rate was determined following Baird et al. [10]. 
Solution-state crystallization rate was determined by a solvent shift method, where 
initially the drug was dissolved in DMSO and the solution was transferred into FaSSIF 
such that the final drug concentration was 1 mg/mL. The drug concentration was 
monitored every 30 minutes by HPLC with a UV detector (analysis performed at 272 nm) 
and a Symmetry C18 column (4.6 mm internal diameter, 150 mm length, 5 μm particle 
size). The mobile phase consisted of 85:15 methanol/water each containing 0.1% 
phosphoric acid and was used isocratically. Amorphous solubility was determined 
following Ilevbare et al. method [124]. The structures of JPC molecules are not shown for 
confidential purposes.  
B.3. Results 
 Several important parameters (i.e. solid-state and solution-state crystallization 
rates as well as amorphous solubility) of JPC molecules are listed in Table B.1. From this 
table, it is clear that these parameters, which subsequently dictate the drug 
bioperformance, can vary greatly even with a subtle variation of functional groups 
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attachment from the parent molecule structure. In general, the solid-state crystallization 
kinetics correspond to those in the solution state, except in the case of JPC-078 where the 
two kinetics significantly differed. The amorphous solubility also greatly varies within 
compounds, indicating that not all compound is suitable for amorphous formulation. 
Although it can be argued that the difference between the amorphous solubility to the 
crystalline solubility is an important parameter when one utilizes amorphous formulation, 
the amorphous solubility value itself is also critical in determining the maximum 
absorbable dose as low solubility would result in low absorption, assuming all other 
factors are constant.  
 
Table B.1. Solid-state and solution-state crystallization rates as well as amorphous 
solubility values of various JPC compounds.  
Compound 
Crystallization rate 
(solid) 
Crystallization rate 
(solution) 
Amorphous solubility 
(ug/mL) 
JPC-068 intermediate fast 13.90 
JPC-077 fast fast 12.00 
JPC-078 fast slow 7.37 
JPC-089 intermediate slow 4.39 
JPC-109 fast fast 1.95 
JPC-141 intermediate slow 212.05 
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APPENDIX C – Tables of Chapter 2 
Table C.1 Thermodynamic properties of various drugs [205, 228, 263]. Tg: glass 
transition temperature, Tm: melting temperature, ∆Hm: enthalpy of fusion, ∆Cp: heat 
capacity difference between the glass and super cooled liquid, ∆H∞: 
equilibrium/maximum relaxation enthalpy, Ta: annealing temperature. 
Compound Tg, K Tm, K ∆Hm, J/g 
∆ Cp, 
J/g/K 
∆H∞, J/g 
∆H∞/∆Hm, 
% 
Tg-Ta, 
K 
Indomethacin 321.0 434.0 110.0 0.37 8.5 9 23.0 
Nifedipine 321.6 445.3 115.2 0.27 6.4 6 23.6 
Flopropione 335.1 414.8 80.2 0.7 26.0 32 37.1 
Glibenclamide 331.0 450.0 108.0 0.45 14.9 14 33.0 
Griseofulvin 364.0 494.0 107.0 0.36 23.8 22 66.0 
Hydrochloriazide 385.0 547.0 104.0 0.31 27.0 26 87.0 
Polythiazide 346.0 493.0 97.0 0.34 16.3 17 48.0 
Indomethacin 317.6 435.2 102.0 0.37 7.3 7 19.6 
Iopanoic acid 315.4 425.6 52.5 0.15 2.7 5 17.4 
Glipizide 331.3 471.5 124.4 0.82 27.3 22 33.3 
Glybendamide 321.6 446.9 112.1 0.40 9.4 8 23.6 
Hydrochlorothiazide 387.3 539.4 126.3 0.38 33.9 27 89.3 
Terfenadine 332.6 423.2 89.9 0.54 18.7 21 34.6 
Griseofulvin 363.3 494.2 107.1 0.29 18.9 18 65.3 
Spironolactone 353.6 480.4 98.4 0.12 6.7 7 55.6 
Danazol 348.0 492.8 94.5 0.18 9.0 10 50.0 
Sulfathiazole 331.1 473.8 112.4 0.44 14.6 13 33.1 
Sulfadimidine 347.3 470.6 125.3 0.51 25.1 20 49.3 
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Table C.2 Maximum relaxation enthalpy and glass transition data for drug/PVP 
dispersions of various compositions annealed at constant temperature (Tg: glass transition 
temperature, Ta: annealing temperature, ∆Cp: heat capacity difference between the glass 
and supercooled liquid, ∆H∞: equilibrium relaxation enthalpy) [264]. 
System Drug Loading, % Tg, K Ta, K 
∆ Cp, 
J/(g*K) 
∆H∞, 
J/g 
Naproxen/PVPK12 100 279.3 278 0.79 1.1 
Naproxen/PVPK12 95.53 309.4 278 0.18 5.7 
Naproxen/PVPK12 90.36 338.1 278 0.24 14.4 
Naproxen/PVPK12 85.68 345.1 278 0.35 23.5 
Naproxen/PVPK12 79.07 339.2 278 0.36 22.0 
Naproxen/PVPK12 70.58 316.4 278 0.38 14.6 
Naproxen/PVPK12 61.06 305.9 278 0.34 9.5 
Naproxen/PVPK12 49.54 314.6 278 0.33 12.1 
Naproxen/PVPK12 27.43 294.5 278 0.32 5.3 
Naproxen/PVPK12 0 370.1 278 0.2 18.4 
      Naproxen/PVPK25 100 279.3 278 0.79 1.1 
Naproxen/PVPK25 94.22 414.6 278 0.25 34.2 
Naproxen/PVPK25 89.61 404.8 278 0.23 29.2 
Naproxen/PVPK25 84.87 390.1 278 0.28 31.4 
Naproxen/PVPK25 78.69 380.2 278 0.28 28.6 
Naproxen/PVPK25 71.22 360.7 278 0.28 23.2 
Naproxen/PVPK25 59.91 341.5 278 0.35 22.2 
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Table C.2 (continued) 
System Drug Loading, % Tg, K 
Ta, 
K 
∆ Cp, 
J/(g*K) 
∆H∞, 
J/g 
Naproxen/PVPK25 50.02 330.1 278 0.36 18.7 
Naproxen/PVPK25 21.9 298.3 278 0.36 7.3 
Naproxen/PVPK25 0 430.2 278 0.21 32.0 
      
Naproxen/PVPK90 100 279.3 278 0.79 1.1 
Naproxen/PVPK90 95.72 433.8 278 0.23 35.8 
Naproxen/PVPK90 90.08 415.8 278 0.26 35.8 
Naproxen/PVPK90 87.72 404.7 278 0.2 25.3 
Naproxen/PVPK90 79.94 391.9 278 0.3 34.2 
Naproxen/PVPK90 69.1 370.2 278 0.29 26.7 
Naproxen/PVPK90 60.06 351.5 278 0.22 16.2 
Naproxen/PVPK90 48.41 333.4 278 0.32 17.7 
Naproxen/PVPK90 26.21 295.4 278 0.38 6.6 
Naproxen/PVPK90 0 451.8 278 0.22 38.2 
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Table C.3 Recovery enthalpy (∆H) and glass transition (Tg) changes in polymer-drug 
dispersions annealed at constant time (ta) and temperature (Ta) [265]. 
System Drug Loading, % Tg, K Ta, K ta, hr ∆H, J/g 
Valdecoxib 100 331.9 313 24 7.95 
Valdecoxib/PVP K29/32 99 332 313 24 6.5 
Valdecoxib/PVP K29/32 98 332.5 313 24 6.3 
Valdecoxib/PVP K29/32 95 333 313 24 6.2 
Valdecoxib/PVP K29/32 90 337 313 24 5 
Valdecoxib/PVP K29/32 85 339.5 313 24 3.1 
Valdecoxib/PVP K29/32 80 344 313 24 2.9 
Etoricoxib 100 333.5 314 24 6.38 
Etoricoxib/PVP K29/32 99 334 313 24 5 
Etoricoxib/PVP K29/32 98 334 313 24 4.8 
Etoricoxib/PVP K29/32 95 335.5 313 24 4.9 
Etoricoxib/PVP K29/32 90 336 313 24 5.1 
Etoricoxib/PVP K29/32 85 338 313 24 5 
Etoricoxib/PVP K29/32 80 342 313 24 4.4 
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